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Abstract of the Dissertation
The role of CDX4 during patterning of definitive hemogenic mesoderm
by
J. Philip Creamer
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2020
Kyunghee Choi, Chair
Christopher Sturgeon, Co-Chair
The current standard of treatment for a variety of hematopoietic malignancies and genetic
disorders is allogenic bone marrow transplantation, where donor hematopoietic stem cells
(HSCs) engraft within the host and give rise to all of them hematopoietic lineages necessary for
homeostasis. In many cases, finding a compatible human leukocyte antigen (HLA) matching
donor is not possible, due to the large amount of genetic variation at those loci, but with the
advent of induced pluripotent stem cells (iPSCs), unlimited sources of patient matched cells can
be derived. Hematopoietic differentiations of human pluripotent stem cells (hPSCs) have been
shown to recapitulate the early development of the embryo, producing known progenitors such
as the hemangioblast, but current efforts have been unable to produce an HSC without the use of
transgene expression. This is partly due to the complex nature of human developmental
hematopoiesis, which is known to contain multiple hematopoietic programs of varying potential.
These programs or ‘waves’ can be generally fit into two categories, the first being
viii

extraembryonic hematopoiesis that occurs within the yolk sac earliest in development and
produces mainly transient, primitive progenitors that support the developing embryo. The
second category is intraembryonic hematopoiesis, which occurs within the embryo proper,
producing more mature progenitors, including the HSC, which arises from hemogenic
endothelium (HE) in the dorsal aorta.
Our lab has developed an hPSCs differentiation model that can identify and specify WNT
independent, extraembryonic, primitive hematopoietic progenitors, and WNT dependent,
intraembryonic, definitive hematopoietic progenitors through stage specific modulation of WNT
signaling during the mesodermal stage of differentiation. I have shown that mesodermal
expression of CDX4, a caudal-like homeobox transcription factor, is an important regulator of
the specification of definitive HE, by utilizing a doxycycline inducible CDX4 hPSC line and a
CDX4y/- KO hPSC line. In this work, I have demonstrated that CDX4 acts to induce canonical
gene targets, such as medial HOXA genes, in different subsets of hemogenic mesoderm, likely
impacting the specification of definitive HE. Surprisingly, TBX20, a cardiomyocyte transcription
factor, was found to be a negatively regulated CDX4 target, suggesting that CDX4 might also
play a role in regulating cardiac specification. I performed cardiomyocyte differentiations and
demonstrated that CDX4y/- KO lead to a significant expansion of cardiomyocytes over WT and
that mesodermal CDX4 expression abrogated this expansion. Additionally, single cell
transcriptomics revealed that CDX4+ mesoderm also expresses CD1D, and when functionally
characterized, definitive CD1D+ hemogenic mesoderm contained nearly all lymphoid, erythroid,
and myeloid potential.
These results will impact the field of hematopoietic differentiation, having extensively
characterized the role of CDX4 in hemogenic mesoderm, it’s gene targets, and correlative
ix

markers. Further studies will be able to leverage CDX4 and its downstream targets, such as
HOXA genes, to improve hematopoietic differentiations, and perhaps improve cardiomyocyte
differentiations by reducing the expression of CDX4.

x

Chapter 1: Rationale, introduction to
developmental hematopoiesis and homeobox
genes
1.1 Hematopoietic stem cells
Hematopoietic stem cells (HSCs) have been rigorously studied for decades for use in life-saving
transplantation, as well as to understand hematopoiesis, and how they contribute to leukemic
transformation in various hematopoietic malignancies. Multipotent progenitors were first
identified in the mouse bone marrow as cells capable of producing clonogenic colonies of
multiple hematopoietic cell types in the spleen of irradiated mice1-4. Further work lead to the
characterization of these bone marrow progenitors via flow cytometry and isolation by flow
cytometry assisted cell sorting (FACS), by removing all cells positive for lineage specific
markers for B cells (B220), granulocytes (Gr-1), monocytes (Mac-1) and T cells (CD4 and
CD8), and positive for Thy1 (CD90)5, Sca16, and c-Kit7. This combination of markers is termed
the Lineage-Sca1+c-Kit+ (LSK) fraction in mice, and a subset of these multipotent progenitors
can be termed as HSCs, being capable of long-term self-renewal, as well as the production of
multiple distinct lineages necessary for maintenance of circulating blood cells from only a single
cell8. Later work in mice showed that an HSC containing population can be further purified from
more lineage restricted progenitors through the use of CD150, CD48, CD229, and CD244 SLAM
family markers9,10. While nascent human HSCs share the expression of markers like CD34, VEcadherin, CD45, C-KIT, and THY-111, the SLAM marker system is specific to mouse HSCs12.

1

The ability of these cells to reconstitute the circulating blood system of an adult has been
exploited as a method of treatment for hematopoietic malignancies13,14 as well as anemias15, and
blood related genetic disorders16,17. Though transplantation can offer treatment and even cures
for many of these patients, these life-saving procedures are hampered by the necessity for high or
complete matching of the human leukocyte antigen (HLA) loci18. This is due to the high level of
variability found in humans at the HLA locus19, making the most likely donor candidates siblings
of the patient; around 30% of patients will have a sibling with the correct HLA genotype to be an
effective donor20, though autologous transplant is preferred in some cases for treatment of
lymphomas21. Because of these unmet deficits in properly matched donors for treatments of
hematological disorders, alternative approaches are needed to close the gap in available
treatment options.

1.2 Human pluripotent stem cells (hPSCs)
Since the discovery of mouse pluripotent stem cells capable of unlimited expansion in vitro,
differentiation into all three germs layers22, as well the ability to produce a viable embryo23,
researchers have been continuously investigating ways to make clinically relevant cell types.
With the discovery of human pluripotent stem cells (hPSCs) derived first from human embryos24
and later through the genetic reprogramming of somatic cells to create induced pluripotent stem
cells (iPSCs)25, it is now possible to produce patient specific iPSC lines with the potential to
differentiate into any replacement cell type needed. Deriving iPSC lines can now be done
without potentially risky gene editing26 and would be syngeneic to patients, preventing immune
rejection in transplanted cell types. Additionally, hPSCs can be used to study early human
development which is very difficult to study for ethic and technical reasons, as they have been
shown to faithfully recapitulate many aspects of both mouse and human hematopoietic
2

development27-29. Despite the lack of a reliably produced, long-term engraftable progenitor,
hematopoietic differentiation protocols have been steadily improved. Although there have been
studies that have been able to produce an engraftable HSC in vitro30,31, they have relied on the
usage of transgene over-expression, which would not be suitable for patient treatments and likely
not faithfully represent the true developmental trajectory. Knowing the key steps in
hematopoietic differentiation during embryological development will shed light on the processes
that are necessary to be able to produce HSCs through in vitro differentiation in a transgene free
manner. The modeling of hematopoietic differentiation in a dish using hPSCs will also help
inform our understanding of human development where in vivo study is not possible.

1.3 Hematopoietic Development
Efforts to recapitulate early human hematopoietic development in vitro have been complicated
by the existence of several distinct programs of hematopoiesis that are spatiotemporally
segregated and given rise to lineages of differing cellular potential. There are multiple, separate
waves of hematopoiesis in humans during early embryogenesis32-34, being either extraembryonic
or intraembryonic in origin. Early anatomical studies of the blood islands in the yolk sacs of
avian embryos noted the possibility of a common progenitor for blood and vasculature term the
hemangioblast35,36. Direct evidence of hemangioblast was seen until much later through in vitro
mouse pluripotent stem cell differentiations that yielded colonies of mixed blood and
endothelium in semi-solid media, termed blast colony-forming cells (BL-CFCs)28, suggesting the
presence of a cell capable of both lineages. Later in vivo mouse embryo studies also
demonstrated the presence of a BL-CFC capable progenitor in the primitive streak, expressing
KDR/Flk1 and brachyury/T 37. The hemangioblast is considered the direct progenitor of
primitive hematopoiesis, as BL-CFC potential is found before the formation of primitive
3

hematopoietic progenitors both in vitro and in vivo, as well as lineage tracing studies
demonstrating primitive hematopoietic cells were derived from KDR+ cells38. It was also found
in mouse PSCs and embryos that ER71/Etv2 acts downstream of KDR/Flk1, as the loss of Etv2
lead to pan hematopoietic and endothelium defects, providing additional evidence of common
regulation of both lineages. Etv2 activation was also shown to be necessary in a brief window in
mesoderm formation before or during the expression of KDR/Flk1 and loss of Etv2 could be
rescued by Scl expression39. Scl expression in KDR+ progenitors has been shown to mark both
blood and endothelium potential, further strengthening Scl as a regulator of the hemangioblast40.
While these studies suggest a mesodermal progenitor that is dually potent for hematopoiesis and
vasculature, there is some evidence against a common origin of endothelium and blood in vivo.
Lineages studies utilizing injections of mouse blastocysts with mixtures mouse PSCs with
recombinase activated fluorescent genes revealed that individual blood islands were nearly
always mixed in origin41, suggested that the hemangioblast could be a mixed population.
Additionally, there is evidence of the production of endothelium from the hemangioblast, that
then gives rise to hematopoietic cells in the mouse yolk sac42, further questioning the presence of
a truly, dually potent hemangioblast.
In humans, primitive hematopoietic progenitors emerge as early as day 19 of conception in
humans43and give rise to primitive erythrocytes mainly expressing epsilon globins44,
megakaryocytes45, macrophages46, and microglia47. Some of the cell types arising from this
program, such as the primitive erythrocytes and megakaryocytes are short lived and are
eventually replaced48, though microglia and macrophages can persist throughout life. This
directly contrasts with the intraembryonic, definitive hematopoietic program that gives rise to an
HSC capable of long-term erythroid-myeloid-lymphoid-megakaryocytic engraftment, first in the
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aorta gonad mesonephros (AGM) region at ~ 5 weeks of development33,49,50 and later in other
hematopoietic tissues. There are, however, several hematopoietic programs that have been
identified that produce lineages not found in the primitive hematopoietic program but are
independent of the HSC. One of these is an extraembryonic lineages that has been extensively
studied in the mouse termed the erytho-myeloid progenitor (EMP)51, which can give rise to more
mature erythrocytes expressing adult globins, granulocytes, and macrophages52. Additionally,
another progenitor termed the lymphomyeloid primed progenitor (LMPP) has also been found in
the mouse yolk sac53, giving rise to myeloid and lymphoid progenitors, which had been thought
to be restricted to the HSC. The production of mature definitive erythrocytes with adult β-globin
expression54 and lymphoid progenitors which were previously thought to be HSC dependent, but
yolk sac in origin, complicates these definitions. Whether to term these progenitors as
‘definitive’ or ‘primitive’ is a difficult question, as well as whether they are present in the
human. Recent work has shown that the mouse EMP is also capable of producing natural killer
cells, another canonically believed lymphoid cell type, that also had a correlate EMP-like
population in hPSC differentiations34. There is also evidence for progenitors capable of adult βglobin expression in the early human fetal liver at 6 weeks, just as the first HSC’s are emerging
and presumably have not had enough time to fully differentiate55. This work doesn’t directly
prove there is a human EMP, though it provides supportive evidence for its existence. All of
these different progenitor populations are summarized in Figure 1.1, adapted from Ditadi et al
(2017)32.

1.4 Hemogenic Endothelium
Hematopoiesis is largely understood to arise from hemogenic endothelium (HE), which
undergoes a process known as the endothelial to hematopoietic transition (EHT)56-59. HE is
5

generally understood to express endothelial markers like CD31/34, but also RUNX1, a
hematopoietic transcription factor60, which primes the endothelium for the EHT59. HE gives rise
to the nascent HSC’s which bud from the dorsal floor of the aorta in clusters and enter
circulation and eventually populate the fetal liver61, where they mature and expand; these cells
will then give rise to all circulating erythroid, myeloid, lymphoid, and megakaryocytic lineages
necessary to sustain the developing fetus, and eventually colonize the bone marrow62.
Hemogenic endothelium is known to not be exclusive to the dorsa aorta; though the
hemangioblast also gives rise to hematopoietic progenitors and endothelium, there is
disagreement in the literature on the origins of HE in relation to the hemangioblast, with the
hemangioblast potentially giving rise to HE42. Since not all HE gives rise to the HSC, it cannot
be used as a term exclusive to definitive hematopoiesis. Complicating matters further, there has
also been reports of HE capable of producing blood progenitors of varying potential in the
human liver and fetal bone marrow63, as well HSCs from the mouse placenta64.
What leads certain HE to give rise to an engrafting HSC, multipotent progenitors, or more
lineage restricted progenitors is not well known, though genetic studies in MYB52 and RUNX165
KO mice suggests that EMP/HSC-producing HE relies on these transcription factors, as only
primitive hematopoiesis is completely unaffected in these models. Additionally, notch signaling
is thought to be required for intraembryonic-HSC producing HE, whereas it appears to be
dispensable for extraembryonic (EMP and primitive) lineages66-68. Notch signaling is important
for the formation of endothelium in dorsal aorta where HE will ultimately arise69, but notch
suppression is actually required for the emergence of the HSC from HE70. Recent work using
single cell transcriptomics of early human embryos computationally identified two different
types of intraembryonic HE, one that appeared to be HSC-primed, and another earlier HE
6

population that lacked arterial markers71. Because HE that gives rise to the HSC is found in the
dorsal aorta, it has been assumed that HE arises from arterial endothelium, though in the
literature there is evidence both supporting an independent origin for HE72, and it originating
from arterial endothelium73.

1.5 Hematopoietic differentiations from hPSCs
Current methods of differentiating hPSCs into hematopoietic progenitors are built on decades of
work first pioneered in mouse embryonic stem cells. Early techniques relied on culture in serum
containing media with free floating aggregates known as embryoid bodies, which induced the
production of many mesodermal lineages including endothelium, blood, and cardiomyocytes74.
Further work characterized the hematopoietic lineages found in these early mouse differentiation
studies, demonstrating the development of primitive erythrocytes and myeloid lineages, that
could be increased with treatment of hematopoietic cytokines such as EPO, IL-3, and MCSF/GM-CSF75. These differentiations follow in vivo hematopoietic development, where
primitive hematopoietic progenitors are produced first, followed by the later emergency of more
mature definitive erythroid progenitors76,77. After the isolation of human pluripotent stem cells,
serum based differentiation approaches were also able to were also of giving rise to the
hemangioblast in BL-CFC assays78, much like mouse PSC differentiations28, indicative of the
primitive program. Later advances in the human system allowed for the development of serum
free media that utilized addition of cytokines including bFGF, BMP4, and VEGF79-81. Usage of
serum free media allows for dissection of the precise signaling requirements needed in order to
specify hematopoietic progenitors, as the numerous factors contained in serum made
understanding these requirements difficult.
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Although it was possible to generate lymphoid cells from mouse embryonic stem cell
differentiations using serum containing media and hypoxic condtions82, hPSCs require a
coculture system with OP9 mouse stroma cells expressing notch ligands to specify T cells83.
Despite later advances in cytokine based serum-free conditions that utilized TGFβ treatment to
specify an endothelial populations capable of definitive erythrocytes and myeloid cells, the
production of lymphoid lineages still requires the co-culture with OP9 stroma with notch
ligands29. Nonetheless, just as in development, this work demonstrated that hPSC differentiations
can produce both primitive/EMP erytho-myeloid potent progenitors and definitive erythromyeloid-lymphoid progenitors if the correct signaling modulations are made in a stage specific
manner.
While this serum free approach in hPSCs gives rise to primitive/EMP CD34+CD43+CD45+
hematopoietic progenitors and CD34+CD31+VECAD+CD43-CD45- definitive HE at certain
timepoints29, it was not possible to purely produce only one or the other. WNT signaling had
been implicated in hematopoietic differentiations previously84, but it was found that stage
specific addition of either WNT antagonists/activin A or WNT agonists during mesoderm
formation lead to the specification of a primitive/EMP hemogenic mesoderm or definitive
mesoderm respectively85. The primitive hemogenic mesoderm was marked by KDR and
glycophorin A (CD235a), giving rise to the hemangioblast and erythro-myeloid potential, while
the definitive hemogenic mesoderm was KDR+ and CD235a-, giving rise to lymphoid, erythroid,
and myeloid potential. This work allowed for precise control of the hematopoietic lineages
produced in culture, differences in signaling requirements, and identification of distinct and
easily segregable mesodermal origins for different waves of hematopoiesis. Interestingly, mouse
embryonic stem cell differentiations also are influenced by agonizing WNT signaling, but this
8

instead promotes the primitive program and represents a key difference between the two
systems86.
Further advances in hPSC differentiation also identified a unique population that contained HE
that was marked by CD34+CD43-CD184-CD73-, that on a single cell level was capable of
lymphoid, erythroid, and myeloid potential and segregated from arterial and venous
endothelium87. These culture conditions are summarized in Figure 1.2 adapted from Sturgeon et
al. (2014)72. With these improvements in technique, it is now possible to precisely interrogate the
genetic regulation behind the specification of hemogenic mesoderm of varying potential.

1.6 Common mesodermal origins for HE and cardiac fates
In the gastrulating embryo, multiple lineages and tissues will be produced from the nascent
mesoderm, including the heart, blood, somites, and endothelium. There are many types of
mesoderm formed, including axial mesoderm, paraxial mesoderm, intermediate mesoderm, and
lateral plate mesoderm88; lateral plate mesoderm gives rise several of these lineages, include
cardiac cells, hematopoietic cells, and endothelium. Because of these common origins, these
lineages share signaling requirements, such as WNT, Nodal, and BMP89-91, for their
specification and development. Cardiac and hematoendothelial progenitors also share expression
of Mesp1, a transcription factor necessary for early mesoderm formation92, as both the heart and
HSCs were marked as Mesp1+ in lineage tracing studies93. It is not clear if there is a single cell
type that is plastic that gives rise to both cardiac and blood/endothelium or if there is a
population of mesoderm containing a mixture of cardiac and hematoendothelial progenitors.
Expression of Brachury (T) and Flk1 (KDR) can segregate these lineages in in vitro PSC
differentiations, suggesting independent origins94, but transgenic activation of notch signaling
was able to respecify hemangioblast containing populations to cardiomyocytes95. Additionally,
9

KO of Scl, a critical pan-hematopoietic transcription factor, lead to the ectopic formation of
cardiomyocytes in the yolk sacs of mouse embryos from CD31+ endothelium96. Scl has already
been identified as a regulator of the hemangioblast, the progenitor of endothelium and primitive
hematopoiesis40 as well as Etv2, which activates Scl39. These studies suggest that within the
developing lateral plate mesoderm, there is a critical balance of a variety of factors that can
swing the balance between hematoendothelial and cardiac lineages. From the literature available,
it is unclear if there is a single cell type that gives rise to hematopoietic, endothelium, and
cardiac lineages, or whether current known mesodermal markers simply represent a mixed
population of already specified mesodermal subtypes.

1.7 Homeobox genes and hematopoiesis
Homeobox genes were first discovered in Drosophila, while trying to clone the genetic locus
responsible for antennapedia mutants, where legs would grow from the head instead of
antennae97. The antennapedia gene contains a helix-turn-helix protein structure, which can
interact directly with DNA at a specific sequence, named the “homeobox”, of which many
homologous and paralogous genes have since been found in vertebrates and invertebrates98,99.
These include the HOX genes, which in mice and humans are linearly organized into four
clusters (A-D) with 39 genes100 that play important roles in axial patterning, limb-specification,
and early development. There are also the ParaHox genes, named for their similarity to HOX
gene clusters and probability as a paralog when discovered as a similar cluster in lancets101. The
ParaHox genes found in mice and humans are the GSX, PDX, and CDX gene families102, which
have been broadly categorized as influencing brain/head, mid sectional, and caudal development
respectively103. Generally, CDX genes have been found to activate during gastrulation in the
early vertebrate embryo and work to activate the expression of HOX genes in a concerted
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pattern of expression anterior to posterior necessary for proper body plan formation104,105. In
humans and mice, there are three CDX genes CDX1, CDX2, and CDX4 which have been shown
to have somewhat compensatory functions106, extending as far complete complementation of
Cdx1 with an in-frame Cdx2 sequence in mice, leading to a normal phenotype107. CDX and HOX
genes have also been shown to be regulated by variety of different signaling pathways in a
variety of different contexts, including fibroblast growth factor (FGF)108, WNT109, retinoic
acid110, and transforming growth factor beta (TGF-β)111. Among their various roles in
development, HOX and CDX genes have been shown to be important for hematopoiesis, in
particular HSC-dependent definitive hematopoiesis. In the zebrafish, cdx4 mutants had early
defects in all hematopoiesis that could be partially rescued with the expression of certain
zebrafish hoxa and hoxb genes112, suggesting that cdx4 plays an important role in the
specification of hematopoietic progenitors. Further in mouse embryos and embryonic stem cells
seems to suggest that loss of Cdx1/2/4 all resulted in defects in specification of
primitive/definitive hematopoietic progenitors coupled with a suppression in HoxA/B gene
expression113,114, but with limited effects on HSCs115. HOXA genes have been specifically
implicated in the regulation of the definitive hematopoietic program in both mouse and hPSC
differentiation models. In particular, the medial HOXA genes, HOXA5,7,9, have been shown to
be critical for human fetal liver HSC function, as well as hematopoietic progenitors differentiated
from hPSCs116. In the mouse and murine embryonic stem cells, the formation of definitive HE
has also been shown to be regulated by HoxA3, forming a regulatory relationship with Runx1, a
critical hematopoietic transcription factor necessary for HSC formation117. This is mirrored in
transcriptional profiling of FACS purified human AGM that displays a distinct HOXA+ gene
signature, which is comparatively found in definitive hematopoietic progenitors differentiated
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from hPSCs118. Within transgene dependent hPSC hematopoietic differentiations, HOX5/7/9 are
also necessary for forming expanded lineage engraftable progenitors from less mature
progenitors30,119, suggesting that HOXA expression is likely required for the specification of an
HSC from HE. Collected together, these results suggest that CDX/HOXA genes are critical for
not only the HSC, but also for the proper patterning of HE that gives rise to the HSC in vivo and
in vitro.
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Figure 1.1: Identified hematopoietic programs in mouse development
Adapted from Ditadi et al. 201632, demonstrating the timing and development of hematopoietic
progenitors of varying potential from different physical locations in the embryo.
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Figure 1.2: Schematic of hPSCs hematopoietic differentiation model system
Adapted from Stugeon et al. 201485, this details the differentiation used throughout this thesis to
specify primitive/EMP hemogenic mesoderm and definitive hemogenic mesoderm and the
lineages that arise from these mesodermal populations.
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2.2 Abstract
The generation of hematopoietic stem cells from human pluripotent stem cells (hPSCs) is a
major goal for regenerative medicine. Achieving this goal is complicated by our incomplete
understanding of the mechanism regulating definitive hematopoietic specification. We used our
stage-specific hPSC differentiation method to obtain and identify, via CD235a expression,
mesoderm harboring exclusively primitive or definitive hematopoietic potential to understand the
genetic regulation of definitive hematopoietic specification. Whole-transcriptome gene
expression analyses on WNT-dependent KDR+CD235a− definitive hematopoietic mesoderm
and WNT-independent KDR+CD235a+ primitive hematopoietic mesoderm revealed strong CDX
gene expression within definitive hematopoietic mesoderm. Temporal expression analyses
revealed that CDX4 was expressed exclusively within definitive hematopoietic KDR+CD235a−
mesoderm in a WNT- and fibroblast growth factor-dependent manner. We found that exogenous
CDX4 expression exclusively during mesoderm specification resulted in a >90% repression in
primitive hematopoietic potential, but conferred fivefold greater definitive hematopoietic
potential, similar to that observed following WNT stimulation. In contrast, CDX4 knockout
hPSCs had intact primitive hematopoietic potential, but exhibited a fivefold decrease in
multilineage definitive hematopoietic potential. Taken together, these findings indicate that
CDX4 is a critical transcription factor in the regulation of human definitive hematopoietic
specification, and provides a mechanistic basis for WNT-mediated definitive hematopoietic
specification from hPSCs.

2.3 Introduction
The generation of hematopoietic stem cells (HSCs) from human pluripotent stem cells (hPSCs)
is a major goal for regenerative medicine. To reproducibly achieve this goal, we must first
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understand human hematopoietic ontogeny. Embryonic hematopoiesis is classically defined by
the spatiotemporal emergence of at least 2 distinct programs.33 The first, primitive
hematopoiesis, does not give rise to HSCs,120 but instead transiently gives rise to a limited
subset of lineages, including HBE-expressing erythroblasts or primitive erythroid colonyforming cells (EryP-CFCs), which can be reliably used as an indicator of the primitive
hematopoietic program.29,85 Shortly thereafter, the definitive program emerges and gives rise to
all lineages found in the adult, including the HSC.49,121 When differentiating hPSCs, the
development of the definitive program can be distinguished from the primitive program by using
in vitro assays for HBG-expressing erythroblasts and T lymphocytes.29 However, the genetic
regulation of human definitive hematopoietic specification, both in vivo and in vitro, remains
unclear.
We recently developed a method to independently specify progenitors of the primitive or
definitive hematopoietic programs from hPSCs via stage-specific manipulation of canonical
WNT signaling.85 This approach generates a WNT-dependent KDR+CD235a− mesodermal
population that gives rise to CD34+ definitive hematopoietic progenitors, as well as a WNTindependent KDR+CD235a+ mesodermal population that gives rise to CD43+ primitive
hematopoietic progenitors. Using this tractable system, we interrogated the transcriptional
regulation of definitive hematopoietic specification at its earliest identifiable mesodermal
progenitor, and identified CDX4 as a critical regulator of human definitive hematopoietic
progenitor specification.

2.4 Methods
Culture and differentiation. The hPSC line H1 (WA01; WiCell) was maintained on irradiated
mouse embryonicfibroblasts in hESC media as described previously78. hPSCs were differentiated
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as described previously72,85. Briefly, hPSCs were MEF-depleted by culturing on Matrigel (BD
Biosciences) in hESC media for 24 hr. Embryoid bodies were generated by treating hPSCs with
trypsin-EDTA (0.05%) for 1 min. Cells were detached by scraping to form small aggregates (6–
10 cells). Embryoid bodies were resuspended in SFD122 supplemented with L-glutamine(2 mM),
ascorbic acid (1 mM), monothioglycerol (MTG, 4x10-4 M; Sigma), holo-transferrin (150
µg/mL), BMP-4 (10 ng/mL), bFGF (5 ng/mL), Activin A (1 ng/mL), and either DMSO (vehicle
control; 0.1%), CHIR99021 (3 µM), or IWP2 (3 µM), as indicated in Figure 1A. Following 72
hrs of differentiation, embryoid bodies were washed with IMDM and then placed in StemPro-34
media supplemented with L-glutamine (2 mM), ascorbic acid (1 mM), monothioglycerol (MTG,
4 × 10−4 M; Sigma-Aldrich), holo-transferrin (150 μg/mL), VEGF (15 ng/mL), IL-6 (10
ng/mL), IGF-1 (25 ng/mL), IL-11 (5 ng/mL), SCF (50 ng/mL), and EPO (2 U/mL final).
Cultures were maintained in a 5% CO2/5% O2/90% N2 environment. All recombinant factors are
human and were purchased from R&D Systems (Minneapolis, MN) except EPO and IGF-1
(Peprotech). Analysis of hematopoietic colony potential via Methocult (StemCellTechnologies)
was performed as described previously29,87.
Genome engineering of hPSCs. Generation of the inducible hCDX4 hPSC line was performed
similar to that previously described, using a 3xFLAG-hCDX4 cDNA123. CDX4 knockout hPSCs,
with a 77bp deletion and frameshift mutation in the first exon of CDX4, were generated using
CRISPR/Cas9 technology. CRISPR guides (http://crispr.mit.edu/)124 were inserted into the
MLM3636 plasmid (Addgene 43860), and along with Cas9 (Addgene 43945) were nucleofected
into H1 hPSCs (Lonza). Single colonies were expanded and screened by PCR.
Endothelial-to-hematopoietic transition assay. CD34+CD43- hemogenic endothelium was
isolated by FACS and allowed to undergo the endothelial-to-hematopoietic transition as
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described previously72,87. Briefly, cells (CD34+CD43- or CD34+CD43-CD73-CD184- cells)
were aggregated overnight at a density of 2x105 cells/mL in StemPro-34 media supplemented
with L-glutamine (2 mM), ascorbic acid (1 mM), monothioglycerol (MTG, 4 ×10−4 M; SigmaAldrich), holo-transferrin (150 μg/mL), TPO (30 ng/mL), IL- 3 (30 ng/mL), SCF (100 ng/mL),
IL-6 (10 ng/mL), IL-11 (5 ng/mL), IGF-1 (25 ng/mL), EPO (2 U/mL), VEGF (5 ng/mL), bFGF
(5 ng/mL), BMP4 (10 ng/mL), FLT3L (10 ng/mL), and SHH (20 ng/mL). Aggregates were
spotted onto Matrigel-coated plasticware and were cultured for additional 9 days. Cultures were
maintained in a 5% CO2/5% O2/90% N2 environment. Hematoendothelial cultures were
harvested by trypsinization and assessed for hematopoietic potential by Methocult.
OP9-DL4 co-culture assay for T-lymphoid potential. OP9 cells expressing Delta-like 4 (OP9DL4) were generated and described previously125,126. Isolated CD34+ CD43- cells were added to
individual wells of a 6-well plate containing OP9-DL4 cells, and cultured for 21-28 days as
described previously29. Briefly, cells were cultured in a-MEM supplemented with 20% FBS,
SCF (30ng/mL, first 5 days only), FLT3L (5 ng/mL) and IL-7 (5 ng/mL). Every four days cocultures were transferred onto fresh OP9-DL4 cells by vigorous pipetting and passaging through
a 40 µm cell strainer. Limiting dilution assays of CD34+CD43- cells was performed on either
control (WT) or CDX4-/Y (KO) hPSCs. 160,000 (n = 2), 100,000 (n = 2), 30,000 (n = 4), 10,000
(n = 4), 3,000 (n = 4), 1,000 (n = 4), 300 (n = 4) or 100 (n = 4) cells were plated for T-lymphoid
assay (biological n = 3). Cultures were assayed following 28 days of co-culture, as above, for the
presence of a CD45+CD4+CD8+ population. Progenitor frequency was calculated by Extreme
Limiting Dilution Analysis (http://bioinf.wehi.edu.au/software/elda/)127.
Gene expression analyses. Total RNA was prepared for whole-transcriptome sequencing using
the Clontech SMARTer kit, and was sequenced with an Illumina HiSeq 2500 with 1x50 single
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reads. Reads were uploaded to the Sequence Read Archive and are available as part of
BioProject PRJNA35244, accession number SRP093125. RNA-seq data was analyzed using the
kallisto/sleuth software suite (https://github.com/pachterlab/sleuth)128. qRT-PCR was performed
as previously described85. Briefly, total RNA was isolated with the RNAqueous RNA Isolation
Kit (Ambion), followed immediately by transcription into cDNA using random hexamers and
Oligo (dT) with Superscript III Reverse Transcriptase (Invitrogen). Real-time quantitative PCR
was performed on a StepOnePlus thermocycle (Applied Biosystems), using Power Green SYBR
mix (Invitrogen). Primer sequences are available upon request. Gene expression was evaluated as
DeltaCt relative to control (ACTB).
Globin analyses. Following 10 days (EryP-CFC) or 14 days (BFU-E) of erythroblast maturation
in Methocult (StemCellTechnologies), individual colonies were picked my mouth pipetting with
a capillary tube. 10 colonies were pooled per biological replicate and assessed for HBG and HBE
expression by qRT-PCR, as previously described85.
Flow Cytometry and Cell Sorting. The antibodies used are all as previously described29,85,87.
KDR (clone 89106), CD4 (clone RPA-T4), CD8 (clone RPA-T8), CD34-APC (clone 8G12),
CD34- PE-CY7 (clone 4H11), CD43 (clone 1G10), CD45 (clone 2D1), CD56 (clone B159),
CD73 (clone AD2), CD184 (clone 12G5) and CD235a (clone HIR-2). All antibodies were
purchased from BD Biosciences (San Diego, CA) except CD34-PECY7 purchased from
eBioscience, CD184 purchased from Biolegend and KDR purchased from R&D systems. Cells
were sorted with a FACSAria™II (BD) cell sorter and analyzed on a LSRii (BD) cytometer.
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2.3 Results and discussion
2.3.1 Mesodermal CDX4 expression is specific to definitive hematopoietic
specification
Given that our hPSC differentiation system gives rise to populations of mesoderm harboring
exclusively primitive or exclusively definitive hematopoietic progenitors (Figure 2.1A)85 we
asked whether these populations could identify which transcription factor(s) regulate definitive
hematopoietic specification within early mesoderm. We isolated by FACS KDR+CD235a− and
KDR+CD235a+ mesoderm, generated by CHIR99021 or IWP2 treatment, respectively (Figure
2.1B)85 and performed whole-transcriptome expression analyses. Differential gene expression
analysis128 revealed significant enrichment of the CDX and HOX genes within definitive
hematopoietic mesoderm (Figure 2.1C, Figure 2.3). CDX1, CDX2, and CDX4 were all highly
expressed in definitive, but not primitive, hematopoietic mesoderm, and have been previously
identified as being expressed during hPSC-derived definitive hematopoietic specification.118
Interestingly, qRT-PCR analyses of each gene over the first 6 days of differentiation revealed
that CDX1 and CDX2 are expressed within 24 hours of differentiation, whereas CDX4 was
instead upregulated twofold at the time of CHIR99021 treatment (Figure 2.1D). CDX expression
immediately decreased following CHIR99021 removal. This suggested that CDX1 or CDX2 may
not specifically regulate definitive hematopoietic progenitor specification, but instead regulate
mesendoderm specification, and thus may affect the emergence of both programs, whereas
CDX4 expression correlates with definitive hematopoietic progenitor specification by WNT
signaling.
In addition to WNT signaling, differentiation cultures at this stage employ the use of BMP4 and
basic fibroblast growth factor (FGF)85,87 both of which contribute to the expression of CDX
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genes in early mesoderm.84,108 Although inhibition of BMP4 signaling with recombinant
NOGGIN caused a complete block in mesoderm formation (not shown), the inhibition of basic
FGF signaling with PD173074 at the same time as CHIR99021 treatment led to the emergence of
a CD34+CD43− population that lacked a distinct CD73−CD184− HE (Figure 2.1E). 87,129
Interestingly, FGF receptor inhibition (FGFRi) had no effect on the expression of CDX1 or
CDX2, but did repress CDX4 expression (Figure 1F). Collectively, these results suggested that
CDX4 is a relevant transcriptional target during human definitive hematopoietic specification.

2.3.2 CDX4 is required for efficient human definitive hematopoietic
specification
In both mouse and zebrafish models, cdx4 deficiency has been implicated in the regulation of
embryonic hematopoiesis.84,112-114,130,131Although Cdx4−/− mice showed no significant definitive
hematopoietic defects,115 zebrafish exhibit a moderate decrease in definitive hematopoietic
potential that was significantly enhanced when combined with cdx1 knockdown112,130,131
suggesting species-specific usage of different Cdx genes during definitive hematopoietic
specification. As we observed definitive hematopoietic mesoderm-specific expression of CDX4
(Figure 2.1C), we reasoned that the role of CDX4 in human embryonic hematopoiesis may be
elucidated using our hPSC model system, by monitoring the ontogeny of primitive and definitive
hematopoietic progenitors from early mesoderm.85
We first generated an inducible expression system using the AAVS1 locus123 to allow for CDX4
expression at any stage of differentiation. Exogenous CDX4 expression from days 2 to 3 of
differentiation (Figure 2.4A) repressed the specification of the primitive hematopoietic
progenitors, as we observed a dramatic decrease in the emergence of CD43+ primitive
hematopoietic progenitors132 (Figure 2.2A), and a 10-fold decrease in detectable EryP-CFCs
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(Figure 2B). Because this resembled CHIR99021 treatment of differentiation cultures,85 which
causes CDX4 expression (Figure 2.1C-D), we asked whether induction of CDX4 expression
during the same window of time would yield a similar effect as CHIR99021 treatment, resulting
in an enrichment of definitive hematopoietic specification.85 Therefore, differentiation cultures
did not have WNT signaling manipulated, so as to allow for the specification of both programs
(Figure 2.1A). Under these conditions, the definitive hematopoietic progenitors were still
specified with doxycycline treatment, because functional CD34+CD43−CD73−CD184− HE87,129
was still specified with similar efficiency to control conditions (Figure 2.2C-D, Figure 2.4B).
However, CDX4 overexpression caused a functional increase within this population, as indicated
by a fivefold increase in definitive erythroid progenitors, similar to that observed following
CHIR99021 treatment (Figure 2.2E). Collectively, these observations indicate that mesodermal
CDX4 expression recapitulates WNT activation during mesoderm specification85 resulting in
definitive hematopoietic specification and primitive hematopoietic repression.
We next used a CDX4 knockout (CDX4−/Y) hPSC line, which completely lacked WT CDX4
expression, whereas CDX1 and CDX2 were still expressed (Figure 2.2F, Figure 2.4D). Under
all differentiation conditions (Figure 2.1A), CDX4−/Y cultures gave rise to approximately
threefold more CD43+ cells (Figure 2.2G). CDX4−/Y hPSCs gave rise to threefold more EryPCFCs in the absence of WNT signaling (Figure 2.2H), likely due to the complete absence of
CDX4 expression in comparison with control IWP2-treated cultures (Figure 2.2F). CHIR99021
treatment still repressed primitive hematopoiesis, suggesting other β-catenin transcriptional
targets also repress primitive hematopoietic specification. In contrast, when CHIR99021-derived
definitive CD34+CD43− cells were assessed for hematopoietic potential, the CDX4−/Y cells
exhibited an approximately sevenfold reduction in HBG-expressing BFU-E potential, and a
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fourfold decrease in myeloid potential (Figure 2.2I, Figure 2.4C). Further, limiting dilution
analyses of T-lymphoid potential revealed a fivefold decrease in lymphoid potential in CDX4−/Y
CD34+ cells (Figure 2.2J), indicating a broad decrease in multilineage definitive hematopoietic
potential.
To determine the cause of this, we asked whether CDX4−/Y hPSCs have either defective HE
specification or an impaired endothelial-to-hematopoietic transition. CDX4−/Y CD34+CD43−
cells exhibited an average fivefold reduction in the specification of CD73−CD184− HE (Figure
2.2K-L), indicating they have impaired definitive hematopoietic specification. However, this HE
population remained functional, giving rise to definitive BFU-E with similar efficiency to control
hPSCs (Figure 2.2M). Because both CDX1 and CDX2 were still expressed under these
conditions (Figure 2.2F), it is possible that either may be redundantly106 contributing to
definitive hematopoietic specification in the absence of CDX4, similar to that observed in
zebrafish.115 Collectively, these results establish that CDX4 is a key regulator of specifying
human definitive hematopoietic progenitors within mesoderm, by regulating the specification of
HE, and thus provides a mechanistic basis for WNT-mediated definitive hematopoietic
progenitor specification.85
CDX/HOX expression has been suggested to be essential for definitive hematopoietic
specification from hPSCs.118,133 Together, our data demonstrate the importance of CDX4
expression for human definitive, but not primitive, hematopoietic progenitor specification within
mesoderm, prior to HE emergence. With this insight, it will be possible to interrogate the
intrinsic and extrinsic regulators of human definitive hematopoietic specification, so as to
ultimately increase hPSC-derived definitive hematopoiesis for regenerative medicine
applications.
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Figure 2.1: CDX4 is expressed at the onset of definitive hematopoietic
progenitor specification within mesoderm.
(A) Differentiation schematic and hematopoietic progenitor identification. hPSCs are
differentiated using a serum-free, stroma-free approach, with stage-specific application of WNT
signal manipulation. Inhibition of WNT signaling within mesendoderm with 3 μM IWP2 leads to
the generation of KDR+CD235a+ mesodermal population, which gives rise to CD43+ primitive
hematopoietic progenitors, whereas WNT activation with 3 μM CHIR99021 generates a
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KDR+CD235a− mesodermal population that gives rise to CD34+CD43−CD73−CD184− HE. No
manipulation of WNT signaling leads to a heterogeneous population of primitive and definitive
hematopoietic progenitors. (B) Representative cell-sorting strategy employed for RNA-seq
analyses. Mesoderm harboring definitive (blue) or primitive (red) progenitors were isolated by
FACS. (C) Heatmap of CDX gene expression within different mesodermal populations, as
determined by RNA-seq. n = 4. (D) qRT-PCR analyses of CDX1 (top), CDX2 (middle), and
CDX4 (bottom) expression during the first 6 days of differentiation as in panel A. Period of
WNT manipulation is shaded in light blue. n ≥ 3 mean ± standard error of the mean (SEM).
Student t test compared with DMSO control: *P < .05. (E) Representative flow cytometric
analysis of CD73 and CD184 expression, gated on CD34+CD43− cells following either
CHIR99021 (CHIR) treatment or CHIR + 1 μM PD173074 (FGFRi) treatment as in panel A. (F)
qRT-PCR analyses of CDX1 (left), CDX2 (middle), and CDX4 (right) expression on day 3 of
differentiation, following treatment with either vehicle (DMSO), CHIR99021 (CHIR), IWP2, or
PD173074 (FGFRi) as in panel A. Normalized to CHIR treatment. n = 3 mean ± SEM. Student t
test compared with CHIR treatment: *P < .05; **P < .01. BMP4, bone morphogenetic protein 4;
DMSO, dimethylsulfoxide; EPO, erythropoietin; IGF-1, insulin-like growth factor 1; IL-6,
interleukin-6; qRT-PCR, quantitative reverse transcription polymerase chain reaction; RNA-seq,
RNA sequencing; SCF, stem cell factor; TPM, transcripts per million; VEGF, vascular
endothelial growth factor.
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Figure 2.2: Mesodermal CDX4 expression is critical for efficient definitive
hemogenic endothelial specification.
(A-E) Analyses of primitive and definitive hematopoietic potential following doxycyclineinducible CDX4 expression via the AAVS1 locus. (A) Representative flow cytometric analysis
of CD34 and CD43 expression on day 9 of differentiation, following IWP2 and doxycycline
treatment from days 2 to 3 of differentiation. (B) Normalized EryP-CFC potential at day 9 of
differentiation as in panel A. n = 3 mean ± SEM. Student t test: ***P < .001. (C) Representative
flow cytometric analysis of CD73 and CD184 expression within CD34+CD43− cells obtained on
day 8 of differentiation, following DMSO treatment, with or without doxycycline, from days 2 to
3 as in Figure 1A. (D) Quantification of CD73−CD184− HE as in panel C. n = 4. Student t test: P
> .05. (E) Quantification of definitive erythroid burst forming unit (BFU-E) potential from 1000
CD34+CD43−CD73−CD184− hemogenic endothelial progenitors, following 9 days of hematoendothelial culture to promote the endothelial-to-hematopoietic transition. n = 3 mean ± SEM.
Student t test compared with DMSO: *P < .05. (F-M) Analyses of primitive and definitive
hematopoietic potential from CDX4−/Y hPSCs. (F) qRT-PCR analysis of CDX1, CDX2, and
CDX4 expression on day 3 of differentiation within wild-type (WT) and CDX4−/Y (knockout
[KO]) hPSCs, following CHIR99021 or IWP2 treatment as in Figure 1A. n = 4 mean ± SEM.
Student t test: *P < .05; ***P < .001. (G) Representative CD34 and CD43 flow cytometric
analyses on day 9 of differentiation following WNT manipulation from days 2 to 3 as in Figure
1A. (H) Primitive hematopoietic potential within day 9 differentiation cultures of WT and
CDX4−/Y (KO) hPSCs, following WNT manipulation as in Figure 1A. n ≥ 4 mean ± SEM.
Student t test compared across WT and KO, per condition: **P < .01; ***P < .001. (I)
Quantification of definitive erythro-myeloid colony-forming potential from CHIR99021-derived
CD34+ progenitors, following 9 days of hemato-endothelial culture to promote the endothelial28

to-hematopoietic transition. Cultures were treated with CHIR99021 from days 2 to 3 as in Figure
1A. Normalized to 10 000 CD34+CD43− day 8 input cells. n ≥5 mean ± SEM. Student t test: *P
< .05. (J) Representative flow cytometric analysis of T-lymphoid potential of WT and CDX4−/Y
(KO) hPSCs, under limiting dilution conditions. Shown is T-lymphoid analyses following 28
days OP9−DL4 coculture under T-lymphopoiesis promoting conditions. Input population shown
is 10 000 CD34+ progenitors. Limiting dilution analyses indicate WT CD34+ cells possess
lymphoid progenitors at a 1:3318 frequency, and KO cells at 1:18 508 frequency. n = 3. P =
.00224. (K) Representative flow cytometric analysis of CD73 and CD184 expression within
CD34+CD43− cells obtained on day 8 of differentiation, following CHIR99021 treatment from
days 2 to 3 as in Figure 1A. (L) Quantification of CD73−CD184− HE as in (K). n > 6. Student t
test: ***P < .001. (M) Normalized definitive BFU-E potential from
CD34+CD43−CD73−CD184− hemogenic endothelial progenitors, following 9 days of hematoendothelial culture to promote the endothelial-to-hematopoietic transition. n = 5 mean ± SEM.
Student t test: P > .05. CFU-E, erythroid colony-forming unit; DOX, doxycycline; n/s, not
significant.

29

Figure 2.3: HOX gene expression differences in mesoderm
Heatmap of HOX gene expression within different mesodermal populations, as determined by
RNA-seq. Populations obtained as in Figure 1B. TPM: Transcripts Per Million. n = 4.
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Figure 2.4: Characterization of iCDX4 and CDX4y/- hPSC lines
(A) qRT-PCR analysis of CDX4 expression following 2 µg/mL doxycycline treatment from days
2-3 of differentiation, as in Figure 1A. n = 3 mean ± SEM. Students t-test compared between no
doxycycline and doxycycline treated cultures * p < 0.05. (B) T-lymphoid potential of the
CD34+CD43- populations derived from day 8 of differentiation cultures, following treatment or
not with doxycycline from days 2-3 of differentiation. Representative CD4 and CD8 flow
cytometric analysis following 21+ days OP9-DL4 co-culture under T-lymphopoiesis promoting
conditions. Gated on CD45+CD56- population. n = 2. (C) Ratio of HBG/HBE expression, as
determined by qRT-PCR, within erythroid colonies derived as in (Figure 2H; “EryP”) and
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(Figure 2I; “EryD”). n = 4 mean ± SEM. Students t-test * p < 0.05. (D) Genome browser
snapshot of the CDX4 locus, showing next generation sequencing of CDX4y/- hPSCs (in red)
compared to WT (in blue), demonstrating the 77 bp deletion as a result of CRISPR Cas9
cleavage.
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Chapter 3: Targets of CDX4 and their role in
promoting definitive hematopoietic
specification and repression of cardiogenic
fate
3.1 Abstract
After having demonstrated that CDX4 is a critical regulator of definitive hematopoiesis, an
interesting question remained: what gene expression changes are resulting from activation of
WNT/FGF dependent CDX4 expression, in the context of definitive hemogenic mesoderm?
CDX4 in human and animal models is generally known act upstream of HOX genes, in particular
HOXA genes112,113,118,131 in hematopoietic development. I hypothesized that CDX4 is binding
directly to target genes responsible for the specification of hemogenic endothelium (HE), such as
in the HOXA cluster, which has shown to be critical for HE117 and HSC function116,118. In order
to find these transcriptional targets of CDX4, I utilized a CDX4y/-, iCDX4 human pluripotent stem
cell (hPSC) line, which overexpresses 3xFLAG-tagged CDX4 upon doxycycline (DOX
induction, to perform paired RNAseq and chromatin immunoprecipitation sequencing (ChIPseq)
on 3xFLAG-CDX4 bound genomic DNA. The sequencing revealed areas of CDX4 binding
during definitive hematopoietic specification in mesoderm, but also allowed me to explore
CDX4 binding in the context of primitive hemogenic mesoderm, as I have shown that CDX4
expression represses the primitive program. By using FACS, I isolated each of these populations:
KDR+CD235a-CD184- definitive, retinoic acid independent hemogenic mesoderm,
KDR+CD235a-CD184+ retinoic acid dependent hemogenic mesoderm, and KDR+CD235a+
primitive hemogenic mesoderm with or without CDX4 expression by manipulating DOX during
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mesoderm formation. As expected, there was broad binding across the HOXA cluster in both
definitive hemogenic mesoderm’s (CD184-/+), but interestingly, there was population specific
HOXA5/7/9 gene expression as a result of CDX4 induction. CYP26A1 were also identified as
being bound upregulated by CDX4, which suggests influence on retinoic acid signaling
respective. CDX4 was also found to be activating CDX2, possibly in a feedback loop within
KDR+CD235a+ primitive hemogenic mesoderm. Intriguingly, TBX20, an important cardiac
transcription factor, was found to be significantly downregulated and CDX4-bound in all three
populations as a result of CDX4 expression, suggesting that CDX4 expression results in
suppression of cardiac lineages. Other cardiomyocyte related genes, such as MESP1 and NKX25, were also suppressed but not CDX4 bound in KDR+CD235a+ mesoderm, which has been
identified as a the progenitor of ventricular cardiomyocytes in previous work134. Further studies
utilizing WT and CDX4y/-, iCDX4 lines differentiated under cardiac promoting conditions
revealed that loss of CDX4 lead to a large increase in cardiomyocyte formation and rescue of
CDX4 expression during mesoderm formation reversed this increase. These data revealed that
CDX4 is regulating HOXA genes as expected within hemogenic mesoderm, but is also
suppressing the specification of cardiac progenitors, through the downregulation of
cardiomyocyte transcription factors like TBX20.

3.2 Methods
Culture and differentiation. Hematopoietic differentiations and functional assays were
performed according to the methods in Chapter 2, with the addition of SB431542 (6 μM)
alongside CHIR99021118.
For cardiac promoting conditions, alterations to the base protocol were adapted from Lee et al.134
Briefly, after aggregation of dissociated hPSCs, cells were suspended in SFD media the same as
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hematopoietic conditions, except containing BMP-4 (5 ng/mL) and Activin A (10 ng/mL) at
indicated concentrations and without addition of CHIR99021 or IWP2. Following 72 hours of
differentiation, cells were washed and resuspending in StemPro-34 media as hematopoietic with
differentiations, except with only VEGF (10ng/mL) and IWP2 (3 µM) for 48 hours. Cells were
then washed, and media exchanged every 3 days until day 12, when cells were transitioned to 5%
CO2 normoxia environment. Media was continued to be exchanged every 3 days, until analysis
was performed at day 20.
Genome engineering of hPSCs. Generation of the CDX4y/-, iCDX4 recue line was generated
using the same strategy as the iCDX4 found in Chapter 2, but into the already established
CDX4y/- KO line also detailed in Chapter 2.
scRNA-seq analyses. Cells from each day 3 differentiation culture condition were methanolfixed as previously described135. Libraries were prepared following the manufacturer’s
instruction using the 10X Genomics Chromium Single Cell 3′ Library and Gel Bead Kit v2 (PN120237), Chromium Single Cell 3′ Chip kit v2 (PN-120236), and Chromium i7 Multiplex Kit
(PN-120262). 17,000 cells were loaded per lane of the chip, capturing >6000 cells per
transcriptome. cDNA libraries were sequenced on an Illumina HiSeq 3000. Sequencing reads
were processed using the Cell Ranger software pipeline (version 2.1.0). Using Seurat136 (version
3.0.2) implemented in R (version 3.5.1), the dataset was filtered by removing genes expressed in
fewer than 3 cells, and retaining cells with unique gene counts between 200 and 6000. The
remaining UMI counts were log normalized and mitochondrial UMI counts were regressed out.
Principal component analysis was used to generate t-distributed stochastic neighbor embedding
(t-SNE) and uniform manifold approximation and project (UMAP) plots. Monocle137 (version
2.10.1) was used for pseudotime analysis. First size factors and dispersions were estimated, and
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then genes were filtered with expression 10 cells. Doublets were removed by filtering out cells
with 24813 total RNA. Cell clustering and trajectory construction were performed using an
unsupervised approach.
Western Blotting. Cells were harvested and then lysed in RIPA-LS buffer containing protease
inhibitors with sonication on ice. After lysis, protein was quantified using BCA quantification
with a BSA standard curve and ~20 μg of protein was boiled in loading buffer and loaded per
sample for PAGE. The protein was then transferred via semi-dry method onto PVDF membrane.
After blocking with BSA, the membrane was staining overnight at 4C using Flag M2 and
αTubulin antibody. After washing with BSA, the membranes were then probe with LI-COR
IRDye secondary antibodies at 4C for 1 hour, followed by additional BSA washes. Membranes
were imagined on a LI-COR Odyssey.
Paired ChIP/RNAseq experiments. After relevant cell types were isolated 0.75x106 cells per
sample were processed according to the beginning steps of Chipmentation138. Briefly, after snap
freezeing at -80C, cells were washed and then formaldehyde fixed at 1% while rocking for 10
minutes at room temperature and quenched by adding glycine to 0.125 M concentration for an
additional 5 minutes at room temp. After centrifugation, cells were resuspended in sonication
buffer (0.25 % SDS) with protease inhibitors and subjected to Covaris microtube sonication,
producing 200-700 bp fragments as assessed by Tapestation analysis. Cells were then diluted
with 1:1.5 with equilibration buffer (10mM Tris, 233 mM NaCl, 1.66 % TritonX-100, 0.166 %
DOX, 1 mM EDTA, with protease inhibitors). Cells were then IP’d rotating overnight at 4C in
RIPA-LS + inhibitor with anti-FLAG antibody and the next day combined with Protein G
Dynabeads for 4 hours. After using magnetic separation to remove the supernatant, the beads
were then successively washed in twice in RIPA-LS, twice in RIPA-HS, twice in RIPA-LiCL,
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and then once in 10 mM Tris pH8. To elute the chromatin, beads were resuspended in ChIP
elution buffer with proteinase K and incubated at 55C for 1 hour and 65C for 6-10 hours. The
supernatant was then transferred to a DNA lo-bind tube, followed by a SPRI bead DNA cleanup
and sequencing performed by core facility. Total RNA was prepared for whole-transcriptome
sequencing using the Clontech SMARTer kit using between 0.75-2.5x105 cells as input. Both
ChIP and RNAseq samples were sequenced on an Ilumina Novaseq S4 XP with 2x150 reads.
Reads from both sample sets was aligned to hg38 reference using the STAR aligner139, for
RNAseq reads were counted using Subread140 and ChIP peaks were called using MACS2141.
Gene Expression analyses. RT-qPCR was performed as described in Chapter 2.
Flow Cytometry and Cell Sorting. Flow cytometry was performed for hematopoietic
differentiations as previously described, using methods from Chapter 2. Intracellular staining
for CTNT was performed as previously described134; briefly, aggregates on day 20 were
dissociated using Collagenase II (0.5mg/ml) overnight, followed by 8 minute Trypsin (0.25%)
incubation at 37C, halted with 5% FCS in PBS. Cells were then fixed for 15 minutes at 4C with
4% PFA in PBS and washed, followed by permeabilization with 90% methanol for 20 minutes at
4C. Cells were then washed, stained with primary antibody at 4C overnight and then washed and
stained with secondary antibody. PDGFRα antibody (clone αR1) was obtained from BD
PharMingen and cTNT (clone 13-11) was obtained from ThermoFisher.

3.3 Discovery of a retinoic-acid dependent hematopoietic
program in hPSCs
In order to better understand the exact cell types that exist within the definitive hemogenic
mesoderm produced within our culture system, our lab performed single cell RNAseq of bulk
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cultures under CHIR99021 and SB431542 (a TGFβ inhibitor, shown to improve CDX/HOXA
expression118) treatment at day 3 of differentiation. After processing through the 10X Genomics
Chromium system and Illumina sequencing, approximately 6,000 unique cells were obtained
after filtering out cells with low read count. To identify these cell types and understand the
relationships between then, the monocle2 software137 was utilized to generate a pseudotime
trajectory in an unbiased manner (Figure 3.1A, adapted from Luff et al. under review142). This
trajectory orders cells based on similarities in gene expression into a low dimensional space to
allow for inference on possible cells state and progenitor/progeny relationships. Each of the
‘branches’ determined by the algorithm were assessed for their cells state by looking for
common germ layer markers, leading to the identification of pluripotent cells (SOX2/NANOG),
ectoderm (TFAP2A, DLX5, KRT7), mesendoderm (SOX2/T) endoderm (FOXA2, SOX17), and
mesoderm (KDR). The cells types farthest along in psuedotime are ectoderm, endoderm, and
mesoderm, following well understood conventions on gastrulation and the development of the
different germ layers143.
One of the more interesting observations from this pseudotime analysis is that there are two
distinct mesoderm branches formed that diverge as pseudotime progresses. Branchpoint analysis
of these two mesodermal populations revealed differential expression of several genes as the
cells progressed from pluripotency to either mesoderm populations (Figure 3.1B, Luff et al.142).
CDX4 and CYP26A1 expression appears to be maintained in expression in one branch, where
CXCR4 (CD184) and ALDH1A2 are expressed in the other opposing branch. CYP26A1 and
ALDH1A2 are important regulators of retinoic acid signaling. Retinoic acid signaling has been
known to play critical roles in embryonic development, in particular in the context of
neurogenesis, eye development, and limb-bud fomation144-146, but also has been implicated has
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having a crucial role in the formation of the HSC147. Retinoic acid signaling depends on
ingestion of Vitamin A (retinol) which is converted first to retinal after transport into the cytosol
by various retinol dehydrogenase (RDH) and then converted to all trans retinoic acid (ATRA) by
alcohol dehydrogenase enzymes (ALDH); ATRA is then bound by RA receptors (RARs) and
retinoid X receptors (RXRs), which translocate to the nucleus and affect gene transcription146.
ATRA is then degraded via a cytochrome P450 (CYP26) enzymes, leading to a halt in
RAR/RXR based gene transcription.
The presence of a high ALDH1A2, low CYP26A1 population, that could be segregated by
CXCR4 (CD184) lead the hypothesis that retinoic acid signaling might be playing a role in this
particular mesodermal population. Initial flow cytometry experiments demonstrated that there
was KDR+CD235a-CD184+ mesoderm at day 3 within our CSB treated differentiations,
confirming these bioinformatic observations (Figure 3.1C, Luff et al.142). FACS isolation of
either KDR+CD184-/+ populations, followed by reaggregation and continued culture for another
five days under previous established conditions72 lead to the production of CD34+ endothelium
from both CD184- (P1) and CD184+ (P2) cells. To test for hematopoietic potential, these CD34+
cells were FACS isolated and either seeded onto OP9-DL4 stroma to test for lymphoid/T-cell
potential29 or into an EHT culture87 followed by plating into methylcellulose to test for
erythroid/myeloid potential. No T-cells were found when CD184+ derived endothelium was
tested for lymphoid potential, while robust CD4/8+ T-cells were derived from CD184mesoderm. Similarly, only small numbers of mainly myeloid colonies were derived from
CD184+ mesoderm, whereas there were large numbers of erythroid and myeloid colonies formed
from CD184- mesoderm (Figure 3.1D, Luff et al.142). This observation correlated with previous
observations of the dependence of definitive HE on mesodermal expression of CDX4, which is
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more highly expressed within CD184- mesoderm. However, with the knowledge that CD184
expression correlated with ALDH1A2 expression, it was hypothesized that CD184+ mesoderm
might require the addition of retinol (ROH) for specification of hematopoietic progenitors.
Addition of ROH to the culture after FACS isolation (P2’) again lead to the formation of CD34+
endothelium from CD184+ mesoderm, but was able to unlock T-cell/lymphoid potential from
this endothelium. Similarly, ROH treated CD184+ mesoderm was able to be produce CD34+
endothelium that give rise to robust erythroid and myeloid colonies after the EHT. Addition of
ROH to CD184- hemogenic mesoderm did not significantly affect the erythroid, myeloid, or
lymphoid potential, suggesting that this population is largely independent of retinoic acid
signaling, correlating with its low levels of ALDH1A2 and higher level of CYP26A1 expression.
The discovery of this novel ROH dependent hemogenic mesoderm raised interesting questions in
terms of the genetic regulation behind the emergence of these populations. CDX4 expression is
heavily downregulated in CD184+ mesoderm, whereas its expression is maintained in CD184mesoderm. Does CDX4 expression promote a ROH independent hemogenic mesoderm or is it
necessary for the emergency of a ROH dependent hemogenic mesoderm? Are there more critical
gene expression differences that segregate these two populations and is it possible that CDX4
could regulating gene expression in different ways in these two populations? In order to answer
these questions and better understand the precise genetic targets of CDX4 in these different
hemogenic progenitors, genetic tools will be needed.

3.4 Establishment of a CDX4-/y, iCDX4 rescue line
After demonstrating the critical role that CDX4 plays in the specification of definitive hemogenic
mesoderm and its suppression of the primitive program (Chapter 2)148, the stage specific role of
CDX4 was not completely addressed by a CDX4-/y KO line or the doxycycline (DOX) inducible
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iCDX4 line. The possibility of CDX4 expression impacting hematopoiesis at later stages of
hematopoietic differentiation could not be entirely ruled out. To address whether mesodermal
expression only of CDX4 would lead to the specification of hemogenic endothelium, a CDX4-/y,
iCDX4 line was generated, combining the AAVS1-based123 DOX-inducible CDX4 with the
endogenous CDX4y/- KO line. This genetic system allows for precise control of CDX4
expression, as there is no endogenous expression and the DOX inducible AAVS1-CDX4 allows
for tunable CDX4 expression. The exogenous CDX4 produced is triple tagged with a FLAG
motif at the 5’ end, allowing for pulldown of CDX4 protein using anti-FLAG antibodies. This
would allow for chromatin immunoprecipitation (ChIP) of CDX4-bound chromatin, to find
where in the genome CDX4 is binding in different mesodermal populations. Commercial
antibodies against human CDX4 showed poor binding affinity and could only be detected
through overexpression of CDX4 (data not shown), necessitating the use a FLAG-tagged
construct. Before ChIP could be performed, it was necessary to shown that 3xFLAG-CDX4
protein can be efficiently expressed, detected, and immunoprecipitated.
To establish that 3xFLAG-CDX4 could be efficiently expressed, protein was isolated from
CDX4-/y, iCDX4 hPSC’s treated with or without 1 μg/ml of DOX and a western blot performed
(Figure 3.2A). The detection of a large anti-FLAG band at ~42 kD was close to the expected
size of CDX4 protein based on size estimates from commercially available antibodies and
ExPASy149. Having established that 3xFLAG-CDX4 can be expressed and detected at the protein
level, confirmation of effective immunoprecipitation (IP) was needed. Bulk day 3 differentiated
CDX4-/y, iCDX4 hPSC’s were harvested for protein, which was then immunoprecipitated used
anti-FLAG protein with magnetic beads. The flow-through from the IP was kept and run
alongside the original lysates, confirming the initial presence of 3xFLAG-CDX4, as well as
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pulldown of CDX4 (Figure 3.2B). Additionally, sonication conditions that yielded 100-500 bp
fragments useful for next generation sequencing and were compatible with the buffers and cell
types used was determined (Figure 3.2C). Finally, functional confirmation of the CDX4-/y,
iCDX4 hPSC was obtained by induction of CDX4 during mesoderm formation and then
functional assessment of erythroid and myeloid potential, as was done previously with the
iCDX4 only line148. Hematopoietic methylcellulose colony forming assays (Figure 3.2D)
revealed that mesoderm induction of CDX4 was able to increase the functional output of
hemogenic endothelium, over non-induced, endogenous CDX4-/y KO.

3.5 Finding CDX4 targets through ChIP/RNAseq
Once the technical conditions for ChIP were found and CDX4-/y, iCDX4 hPSC’s were
functionally confirmed, combined ChIP and RNAseq could be performed on the relevant
mesodermal populations. Since a unique, retinol responsive KDR+CD235a-CD184+ hemogenic
mesoderm was discovered through observations from our lab (Luff et al, in review142), analysis
of this population and the potential role that CDX4 could play in its formation was of great
interest. FACS isolation of both CD184- ROH independent and CD184+ ROH dependent
definitive hemogenic mesoderm would allow for assessment of the role CDX4 in both of these
populations simultaneously. Additionally, understanding how enforced mesodermal expression
of CDX4 results in repression of the primitive program could yield insight into other key
mesodermal regulators of definitive/primitive hematopoiesis. Answering these questions will
require FACS isolation of three different populations: KDR+CD184- ROH independent,
KDR+CD184+ ROH dependent, and KDR+CD235a+ primitive hemogenic mesoderms (Figure
3.3A). Paired RNAseq of each of these populations in biological triplicate would allow for
correlation of CDX4-bound chromatin with changes in gene expression, to rule out the
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possibility of CDX4 binding, but not inducing transcription. A control population without
DOX/CDX4 induction would serve as the control population for ChIP and RNAseq, creating
technically paired samples, resulting in a total of six different populations. Because of the
technical limitations of sorting large amounts of these mesodermal populations that are
approximately ~30-40% of the total numbers of cells within the culture, a ChIP protocol that was
designed to use a low input was (in part) adapted for this experimental design138. A target
population of 0.75x106 cells was sorted for each ChIP replicate and between 0.75-2.5x105 sorted
for each RNAseq replicated.
After the ChIP was performed and the RNA extracted, the samples were submitted for a target of
~30 million reads on an Illumina Novaseq with 150bp paired end reads. The ChIP samples were
aligned to the hg38 reference using the STAR aligner139, and triplicate samples were combined
to increase the read counts at any given locus and aid in peak calling. To find peaks where CDX4
protein was bound, the program MACS2 was used to call peaks in CD184-, CD184+, and
CD235a+ sets in comparisons to background reads provided by the no DOX control141. The
RNAseq reads were aligned to hg38 reference using STAR139 and reads counted and assigned to
genes through Subread140. Global analysis of regions of significant CDX4-bound regions was
visualized using deepTools150, demonstrating that the majority of CDX4 binding in all three
populations was just upstream of the transcriptional start site (TSS), as expected for a
transcription factor (Figure 3.3B). Interestingly, the KDR+CD235a+ ChIP samples had more
dispersed binding just downstream of the TSS when compared to either of the definitive
hemogenic mesoderm (CD184-/+). This could possibly be due to the exogenous expression of
CDX4 that is not normally found within this population, perhaps causing spurious binding
beyond the TSS.
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3.6 HOXA and retinoic acid processing genes are CDX4
targets
To find more precise targets of CDX4, significant peaks called by the MACS2 software were fed
into GREAT analysis151, correlating peaks with the closest nearby genes. Within a shorter given
range (5 kilobases upstream, 1 KB down), peaks could be associated with more than one gene’s
TSS, otherwise longer-range interactions were captured by extending the range up to 1000 KB
until the TSS of a gene was reached. Approximately 2105 genes were associated with a CDX4
peak in the KDR+CD184- samples, 1435 genes for the KDR+CD184+ samples, and 8757 genes
for the KDR+CD235a+ samples. To narrow down these large numbers of gene-associated peaks
and determine which are potentially influencing transcription, changes in RNAseq for each
sample set were cross referenced (RPKM > 1, fold change > 1.5, p value < 0.05) with these
peaks. After this analysis, the CD184- samples had 15 CDX4 gene putative targets (up and
downregulated), the CD184+ samples had 71 targets, and the CD235a+ samples had 892 putative
targets (Table 1, top 10).
Because of the established relationship of CDX and HOXA genes in hematopoietic
context105,112,116,117,130,133, the HOXA cluster was examined first. Large numbers of significant
peaks were found across the majority of the locus, in all three sample sets (Figure 3.4A),
particular near HOXA4, 5, 7, and 9. Interesting, HOXA gene expression changes as a result of
CDX4 induction was differential depending what type of hemogenic mesoderm it was expressed
in (Figure 3.4B). Despite strong peaks near HOXA4, there was poor expression in all sample sets
and did not change as a result of CDX4 induction (data not shown), while HOXA7 was induced
in the CD184- mesoderm and HOXA5/7/9 were induced in the CD184+ mesoderm. The limited
change in expression in the CD235a+ population was expected as this population has little to no
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HOXA expression under basal conditions and the lack of WNT signaling might result in a lack of
cofactors necessary to effect gene transcription.
With the understanding that KDR+CD184-/+ hemogenic mesoderms have established
differences in expression of retinol processing enzymes (Figure 3.1, Luff et al.142), genes that
were important for ROH signaling were assessed as CDX4 targets. CYP26A1, the gene
responsible for breaking down retinoic acid, was found to have a significant peak in the CD184+
mesoderm, but not in the other populations (Figure 3.4C). This correlated with a significant
increase of CYP26A1 to comparable levels found in the CD184- retinoic acid independent
hemogenic mesoderm, which were not significantly impacted by CDX4 induction (Figure 3.4D).
Although the levels of CYP26A1 expression are still much lower in comparison to CD235a+
primitive hemogenic mesoderm, this suggests that CDX4 might be influencing the
responsiveness of the CD184+ mesoderm to retinoic acid signaling.

3.7 CDX4 is regulating CDX2 and TBX20
Investigating the other genes found to be CDX4 targets within the CD184- mesoderm, where the
highest levels of CDX4 expression are found endogenously, revealed that CDX2 was a target of
CDX4. (Figure 3.5A), and RNAseq revealed a modest, but significant increase in CDX2
expression as a result of CDX4 induction (Figure 3.5B). In the mouse embryo, exogenous
expression of Cdx2 was found to bind to the Cdx4 promoter and induce Cdx4 expression through
WNT mediated feedback152. Interestingly, significantly upregulation of CDX2 was not found in
either CD184-/+ mesoderm, possibly because of already high levels of expression due to WNT
activation, which is known to induce CDX expression153. This suggests there might be a CDX2CDX4 feedback loop, though CDX2 acting as a transcription factor for CDX4 has not been
established in the context of human hemogenic mesoderm.
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Looking at the CDX4 targets identified in the CD184- mesoderm, it was surprising to see 2 out of
15 genes downregulated as a result of CDX4 induction, as well as having nearby CDX4 binding
peaks. CDX genes are canonically transcription factors that lead to gene induction, though there
might be some evidence of CDX genes acting as repressor in concert with epigenetic regulators
such BRG1-SWI-SNF154, which has been known to occasionally act in a repressor role155. One of
the two genes identified as CDX4 repressed was TBX20, an important cardiac transcription factor
necessary for proper heart structure156,157. A significant peak for both CD184- and CD235a+
mesoderm was found downstream of TBX20 in the intron of another gene (Figure 3.5C),
interestingly all three mesodermal populations also displayed a decrease in TBX20 expression as
a result of CDX4 induction (Figure 3.5D). Although the same peak was not considered
significant for the CD184+ mesoderm, this could be due to noise or variation in samples that lead
to the MACS software as not calling it significant. This possible suppression of a cardiac
transcription factor in a CD235a+ mesoderm is intriguing, as recent work has shown that
ventricular cardiomyocytes arise from a CD235a+ mesoderm in an hPSC differentiation model
system134. This is supported by studies in mouse embryos/embryonic stem cells158 as well as the
zebrafish159 that show that Cdx1/2/4 gene expression negatively regulates cardiogenesis,
resulting in disruptions in heart structure and decreased cardiac related gene expression. Since
CDX2 was also upregulated through enforced CDX4 and both genes are implicated in
downregulating various cardiomyocyte transcription factors, examination of the CD235a+
RNAseq alone revealed downregulation (but not CDX4 binding) for NKX2-5, MESP2, and
interestingly GPYA (CD235a). NKX2-5 is a critical cardiac transcription factor160 and MESP1/2
are known to mark mesoderm capable of cardiac specification92. Since these genes were not
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bound by CDX4, the decrease due to enforced CDX4 expression (Figure 3.5E) is due to indirect
effects from CDX4, possibly as a result of increased CDX2 expression.

3.8 CDX4 expression leads to a decrease in cardiac
specification
Having discovered evidence that CDX4 expression in certain mesodermal populations leads to
repression of several cardiomyocyte transcription factors, it became obvious to test whether
mesodermal CDX4 expression could lead to a functional repression in the formation of cardiac
progenitors. In order to test this hypothesis, both WT and CDX4y/-, iCDX4 hPSC’s were
differentiated under established conditions for the specification of PDGFRα+CD235a+
ventricular cardiac mesoderm134. Mesoderm was specified from days 0-3 under very similar
conditions as hemogenic mesoderm, but with lower levels of BMP4 (5 ng/ml) and higher levels
activin A (ACTA, 10 ng/ml) and from days 3-5, treatment of the WNT inhibitor IWP2. On day
5, PDGFRα and CD235a expression was assessed via flow cytometry demonstrating that WT
and CDX4y/-, iCDX4 (with or without DOX from days 2-3) hPSCs were all capable of producing
PDGFRα+CD235a+ cardiac mesoderm at ~30% efficiency (Figure 3.6A). Seeing no phenotypic
differences in the mesoderm produced, qPCR analysis of bulk day 5 culture revealed that
expression of TBX5, an important cardiomyocyte transcription factor161, was significantly
reduced as a result of CDX4 expression during days 2-3 (Figure 3.6B). Interestingly, there was
no difference in TBX20 or NKX2-5 expression at day 5, although DOX induced CDX4
expression had already dropped to nominal levels, perhaps allowing for recovery of expression in
these genes. Despite no functional differences in CD235a based on flow cytometry, there was a
decrease in GYPA (CD235a) expression as a result of CDX4 induction. This could be due to a
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long half-life of CD235a protein, which in some cell types could be up to 48hrs162, and might be
reduced later in the differentiation.
Further maturation of the cardiac differentiations to days 8-12 produced spontaneously beating
embryoid bodies (EBs), indicating that cardiomyocytes were present. WT differentiations had
sparse numbers of beating EBs, while the CDX4y/-, iCDX4 hPSC’s had a significantly higher
amount, that was reduced when DOX was applied from days 2-3. While informative, this
observation was not easily quantifiable, and the presence of cardiomyocytes can be better
assessed through intra-cellular flow cytometry of cardiac specific troponin T (cTNT). On day 20,
differentiations were harvested, fixed/permeabilized, and stained for CD90 (to exclude
endothelium) and cTNT. WT hPSCs had a low level of cardiomyocytes present, at ~5% CD90cTNT+ cells at day 20 (Figure 3.7A), in comparison to ~30% CD90-cTNT+ cells in CDX4y/-,
iCDX4 differentiations. This expansion in cTNT+ cardiomyocytes was reduced to WT levels
after induction of CDX4 through application of DOX only from day’s 2-3 (Figure 3.7B),
demonstrating that mesodermal CDX4 expression can suppresses the formation of
cardiomyocytes, and its loss leads to their expansion. qPCR of day 20 differentiations also
demonstrated a reduction in cTNT transcriptionally and expression of MYL2, a ventricular
specific cardiomyocyte gene163 (Figure 3.7C). Collectively, these results demonstrate that
mesodermal CDX4 leads to a repression in ventricular cardiomyocyte specification, likely
directly through the repression of TBX20 and indirectly through CDX2.

3.9 Discussion
The data generated from these ChIP/RNAseq experiments yielded several insights into how
CDX4 regulates the development of multiple mesoderm-derived lineages. As expected based on
the literature surrounding CDX-HOXA genes in the context of hematopoiesis112,117-119,130,133,
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CDX4 is indeed leading to induction of several HOXA genes, in particular medial HOXA genes
(5/7/9). The medial HOXA genes have been demonstrated to be induced in both CD184- retinoic
acid independent hemogenic mesoderm (HOXA7) and within CD184+ retinoic acid dependent
mesoderm (HOXA5/7/9). This differential response to induction of CDX4 suggests that other cell
intrinsic factors could be influencing which HOXA genes are being induced when CDX4 binding
within the locus. The HOXA locus has complicated gene regulatory mechanisms that influence
which genes are induced, generally in a colinear manner starting with HOXA1-HOXA13 in an
anterior to posterior pattern within in the embryo105. This is thought, in part to be due to CTCFmediated looping that results in PRC-dependent gene silencing and further impacted by retinoic
acid signaling164. Since neither of these three mesodermal progenitor populations was exposed
to ROH or retinoic acid before being harvested for sequencing, it is unlikely at this particular
stage of development that ROH signaling is influencing the population specific HOXA gene
expression.
Based on the basal level of HOXA5 and HOXA9 expression in the KDR+CD184- uninduced
CDX4y/-, iCDX4 mesoderm, it appears that CDX4 induction in the KDR+CD184+ mesoderm
resulted in expression levels that match KDR+CD184- mesoderm. CYP26A1 expression was also
induced to a similar level as the KDR+CD184- population, when CDX4 was enforced in the
KDR+CD184+ mesoderm. These data suggest that when CDX4 is exogenously expressed within
KDR+CD184+ retinoic acid dependent mesoderm, it takes on a HOXA/CYP26A1 gene
expression profile similar to CD184- retinoic acid independent mesoderm. Although extensive
functional characterization would be needed, this suggests CD184+ mesoderm could be
converted into a ROH-independent hemogenic mesoderm, where the exogenous expression of
CDX4 causes an override of the ROH-dependent program. Genetic-epistasis studies would be
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needed to fully confirm the population-dependent nature of induction of HOXA5/7/9 by CDX4,
which could be addressed through complementation of the CDX4y/- KO with inducible
HOXA5/7/9 constructs.
Perhaps the most unexpected gene target of CDX4 was TBX20, an important cardiac transcription
factor156,157, which was consistently downregulated by CDX4 expression in all three mesodermal
populations. The most striking CDX4 binding peak however, was the CD235a+ mesoderm,
which having been shown to be the progenitors for ventricular cardiomyocytes134, leading me to
hypothesize that CDX4 could be repressing the cardiomyocyte program. Having demonstrated
that mesodermal CDX4 expression leads to the suppression of cardiac specification, it is still
unclear if this suppression is due to a lack of contribution from KDR+CD235a+ mesoderm. In
cardiac differentiations, day 5 is when CD235a+ cells are assessed, after WNT inhibition from
days 3 to 5. It is unclear whether CD235a+ mesoderm maintains CD235a expression and gives
rise to the CD235a+ cells found on day 5, or whether this is a different population that emerges
later. FACS isolation of KDR+CD235a+ mesoderm on day 3, followed by continued culture
could address the question of where ventricular cardiomyocyte progenitors are coming from on
day 3.
Another unaddressed question in these experiments was the role CDX4 plays in the specification
of atrial cardiomyocytes, which have been shown to be dependent on ROH-signaling for their
formation134. Since CD184+ mesoderm has been shown by our lab to be dependent on ROH for
the specification of hematopoietic progenitors, perhaps this population also contains the
progenitors for atrial cardiomyocytes134. Again, FACS isolation of CD184+ mesoderm under
cardiogenic conditions on day 3, followed by treatment of ROH could perhaps answer this; the
role of CDX4 in ROH-dependent hematopoiesis has also not been established.
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Figure 3.1: CD184 expression marks a retinol responsive,
CDX4lo mesodermal population
(from Luff et al., in review142) A. scRNAseq was performed on bulk culture treated with
CHIR99021 and SB431542 (TGF inhibitor) at day 3, after the specification of mesoderm to
better assess the culture heterogeneity and to find hemogenic mesoderm. Briefly, the cells were
dissociated via trypsin and fixed in methanol, before being processed via 10X Genomics
Chromimum 3’ kit, capturing >6000 cells. The libraries were sequencing via an Illumina HiSeq
3000 and processed via the Cell Ranger pipeline. The R package Monocle2 was used to generate
an unsupervised pseudotime plot with branchpoints. B. A heatmap of expression in cells across
the peusdotime plot, ranging from population 1 (pluripotency) to either mesoderm populations
identified after the branchpoint, showing an inverse correlation between CDX4 and CXCR4
(CD184) and ALDH1A2. C. Flow cytometry of day 3 mesoderm after CHIR99021/SB431542
treatment, showing two different mesodermal populations, CD184- (P1) and CD184+ (P2).
FACS isolation of these two populations and continued culture shows both give rise to CD34+
endothelium populations, which there then assessed for lymphoid potential by further coculture
with OP9-DL4 for 29 days and harvested for flow cytometry. D. All three populations were
FACS isolated at day 8 (CD34+) and placed into an EHT assay for an additional 9 days and then
plated into hematopoietic methylcellulose media. The numbers of colonies were then assessed
after 12-14 days and the numbers were counted of burst forming units erythroid (BFU-E) and
colony forming units (CFU) of erythroid (E), granulocyte (G), myeloid (M), and mixed
granulocyte/myeloid (GM). n = 3, ** p < 0.01 via students t test of BFU-E. All Error bars SEM.
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Figure 3.2: Doxycycline inducible, FLAG-CDX4 can be
immunoprecipitated effectively in day 3 mesoderm
y/-

A. Protein isolated from CDX4 , iCDX4 hPSCs was isolated and quantified, with or without 24
hours of 2 μg/ml doxycycline (DOX) and 20 μg of protein was loaded to each well from the
corresponding sample for SDS-PAGE. After western blot transfer, the membrane was blocked
and probed with anti-Tubulin and ant-FLAG primary antibodies, IRDye secondary antibodies,
and imaged on a LICOR Odyssey. B. Western blot of protein (20 μg) isolated from day 3 bulk
y/-

differentiation from CDX4 , iCDX4 hPSCs for immunoprecipation (IP), which was preformed
using anti-FLAG antibody and Protein G bound magnetic beads. DOX treatment was performed
for 30 hours, from Day 2 to Day 3. Input denotes protein samples pre-IP, flow thru denotes the
supernatant removed after the IP, and IP denotes the protein removed from the beads. CDX4
bands highlighted in blue. C. TapeStation size analysis of genomic DNA fragments of day 3
y/-

differentiated CDX4 , iCDX4 hPSCs after lysis and formaldehyde crosslinking. Far left lane
y/-

ladder, middle control with no DOX added, and 2 μg/ml of DOX from days 2-3. D. CDX4 ,
iCDX4 hPSCs were differentiated as described before with CHIR99021 (CHIR), with or without
the addition of 2 μg/ml DOX from days 2 to 3 and continued until day 8 of culture. The cells
were harvested and CD34+CD43-CD184-CD73- HE was sorted as previously described and
plated and reaggregated for an additional 9 days in EHT culture. Cells were then harvested and
plated in hematopoietic methylcellulose media for 10-12 days and the numbers were counted of
burst forming units erythroid (BFU-E) and colony forming units (CFU) of erythroid (E) and
myeloid (M) colonies. * indicates p < 0.05 via student’s T test between BFU-E, n =5, error bars
SEM.
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Figure 3.3: Finding CDX4 gene targets through
ChIP/RNAseq
y/-

A. Schematic of the different populations isolated for paired ChIP/RNAseq; the CDX4 , iCDX4
hPSC line was cultured under four different conditions: CHIR99021/SB431542 treatment to
induce definitive hemogenic mesoderm, with or without 1 μg/ml doxycycline (DOX) from days
2-3 to induce iCDX4, or IWP2 treatment to induce primitive hemogenic mesoderm, with or
without DOX. KDR+CD235a-CD184- and KDR+CD235a-CD184+ cells were then FACS
isolated from the definitive cultures and KDR+CD235a+ isolated from the primitive cultures.
These six populations were isolated in biological triplicate and subjected to paired
RNAseq/ChIPseq via anti-FLAG pulldown of CDX4 protein. B. After alignment of the ChIPseq
reads, the software package deepTools was used to generate heatmaps of pulled down reads
across all known genes in the genomes by taking each of the three populations respective
populations and normalizing to the paired biological control (no DOX), where red indicates
greater relative enrichment and blue low enrichment. The histogram plot at top was generated by
taking the relative enrichment at positions from -2 to +2 kilobases from the transcriptional start
across all genes, scale arbitrary.
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Figure 3.4: CDX4 is binding at HOXA and CYP26A1 loci, but
inducing expression differentially across populations
A. Genome browser view of the HOXA cluster found on chromosome 7, displaying the CDX4
ChIP reads for KDR+CD184- (Blue), KDR+CD184+ (Green), and KDR+CD235a+(Red)
samples, with the CDX4 DOX induced samples read pileup in maroon, compared to controls in
grey. Highlighted are several regions denoting highly significant peaks called by the MACS2
software in the samples when compared to the no DOX controls. B. Gene expression of HOXA
genes in RPKMs from the RNAseq paired with the ChIP samples; KDR+CD184- highlighted in
blue, KDR+CD184+ highlighted in green, and KDR+CD235a+ highlighted in red. n = 3, error
bars SEM, * is p < 0.05, ** p < 0.01 via students T test, error bars SEM. C. Genome browser
view of the CYP26A1 locus on chromosome 10, displaying read pileups from ChIPseq performed
on KDR+CD184 (Blue), KDR+CD184+ (Green), and KDR+CD235a+(Red) samples. Sample
tracks with DOX induced FLAG-CDX4 highlighted in maroon, compared to controls in grey.
MACS2 significant peaks highlighted in blue. D. Gene expression of CYP26A1 in RPKMs from
the RNAseq paired with the ChIP samples; KDR+CD184- highlighted in blue, KDR+CD184+
highlighted in green, and KDR+CD235a+ highlighted in red. Left plot shown without
KDR+CD235a+ samples and right plot with. n = 3, error bars SEM, ** is p < 0.01 via students t
test, error bars SEM.
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Figure 3.5: CDX4 is regulating CDX2 and TBX20, a cardiac
transcription factor
Genome browser view of the CDX2 locus on chromosome 13, displaying read pileups from
ChIPseq performed on KDR+CD235a (Red). Sample tracks with DOX induced FLAG-CDX4
highlighted in maroon, compared to controls in grey. MACS2 significant peak highlighted in
blue. B. Gene expression of CDX2 in RPKMs from the RNAseq paired with the ChIP samples
KDR+CD325a+ highlighted in red. n = 3, error bars SEM, * is p < 0.05 via students t test, error
bars SEM. C. Genome browser view of the TBX20 locus on chromosome 7, displaying read
pileups from ChIPseq performed on KDR+CD184- (Blue) and KDR+CD235a+ (Red). Sample
tracks with DOX induced FLAG-CDX4 highlighted in maroon, compared to controls in grey.
MACS2 significant peaks highlighted in blue. D. Gene expression of TBX20 in RPKMs from
the RNAseq paired with the ChIP samples KDR+CD184- highlighted in blue, KDR+CD184+ in
green, and KDR+CD235a+ in red. n = 3, error bars SEM, * is p < 0.05 via students t test, error
bars SEM. E. Gene expression of various cardiac related transcription factors in RPKMs from
the RNAseq paired with KDR+CD235a+ ChIP samples. n = 3, error bars SEM, * is p < 0.05, * p
< 0.01 via student t test, error bars SEM.
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Figure 3.6: CDX4 expression during mesoderm formation
leads to repression of cardiac factors under cardiogenic
conditions
y/-

A. WT and CDX4 ,iCDX4 hPSCs (w/ or w/out 1 μg/ml DOX from days 2-3) were differentiated
under cardiogenic conditions under hypoxia similar to previous hematopoietic conditions, with
the same media base except alterations to cytokine concentration. B. Bulk culture of CDX4

y/-

,iCDX4 hPSCs (w/ or w/out 1 μg/ml DOX from days 2-3) was harvest at day 5 for RNA and
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cDNA generated for RT-PCR. All genes were normalized relative to ACTB expression, n = 3, * is
p < 0.05, ** is p < 0.01, ns is not significant, via students t test, error bars SEM.
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Figure 3.7: Mesodermal CDX4 expression leads to
suppression of cardiomyocyte formation
y/-

A. WT and CDX4 ,iCDX4 hPSCs (w/ or w/out 1 μg/ml DOX from days 2-3) were differentiated
under cardiogenic conditions under hypoxia similar to previous hematopoietic conditions, with
the same media base except alterations to cytokine concentration. At day 20, cells were
disassociated, fixed/permeabilized and then stained for CD90 and cTNT for flow cytometry,
shown are all cells negative for CD90. B. Quantification of flow cytometry on day 20
y/-

differentiated WT and CDX4 ,iCDX4 hPSCs (w/ or w/out 1 μg/ml DOX from days 2-3) for
y/-

CD90-cTNT+ cells. WT n =2, CDX4 ,iCDX4 n = 5. **** indicates p < 0.0001 between control
y/-

and DOX treated CDX4 ,iCDX4 hPSCs via students t test, error bars SEM. C. T20 cardiac
y/-

differentiations from CDX4 ,iCDX4 hPSCs (w/ or w/out 1 μg/ml DOX from days 2-3) were
harvested for qPCR. Expression normalized to ACTB, n = 3, * p < 0.05, ** p < 0.01, error bars
SEM.
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Table 3.1: List of CDX4 target genes in different hemogenic
mesoderm populations
For each population, the genes that were associated (GREAT analysis151) with significant CDX4
peaks (MACS2141) and had a 1.5 fold change in RPKMs (>1, p < 0.05) when compared to their
respective control population are listed below, segregated into genes that are upregulated with
CDX4 induction and those that were downregulated.
KDR+CD184Upregulated with CDX4

KDR+CD184+

KDR+CD235a+

Upregulated with CDX4

GNRH2

Downregulated
with CDX4
ALPK2

Upregulated with CDX4

ABCG2

Downregulated
with CDX4
ALDH1A2

43891

Downregulated
with CDX4
43901

GREB1

NFE2

ANGPT1

ALPK2

43893

ABTB2

HOXA7

SLN

ARHGAP10

HAS2

AAMDC

ACKR3

LMO2

TBX20

ARID5B

LRRN1

ABCC5

ADA

NAV1

C3orf52

PITX2

ABCG2

ADGRD1

PC

CEP97

PODXL

ABHD12

ALG1L

PDE4D

CYP26A1

RSPO2

ABHD5

ALPK2

PLXNA2

DHRS3

SBSPON

ADD2

AMOTL1

TGFBI

DUSP5

TBX20

ADGRE5

ANGPT2

TMPRSS11E

ELL2

ADGRL4

ANKH

TRPA1

EPB41L4A

ADIPOR1

ANKRD1

EPHA4

AGPS

ANXA8L1

ERC2

AGTPBP1

APCDD1L

ETV1

AHCYL2

APLNR

FAM188A

ALCAM

AQP3

FST

ALDH1A1

ARHGAP32

FZD6

ALDH3A2

ARHGAP40

GAP43

ALDH4A1

ARL4D

GOLIM4

ALDH6A1

ASH2L

GREB1

ALDH9A1

B3GALT1

GUCY1A3

ALS2

BAG3

HAND2

AMIGO2

BCAR3

HOXA5

ANKRD6

BIN1

HOXA7

AP2B1

BMP2

HOXA9

AP4E1

BMP4

HOXB4

APLP1

BMPER

HOXB7

APOL2

BRINP1

HOXC4

APOOL

C14orf132

HTR2B

ARHGAP10

C1GALT1
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Chapter 4: CD1d marks CDX4+ mesoderm
4.1 Abstract
Having shown that CDX4 is a critical regulator of definitive hemogenic mesoderm148, a critical
question remained: does CDX4+ mesoderm ultimately give rise to definitive hematopoietic
mesoderm, or does it’s expression act in supportive manner in other cell types that do not
directly give rise to hematopoiesis? Creating a CDX4 reporter that would label all CDX4+ cells
with a fluorescent protein would allow for the purification of CDX4 expressing mesoderm
through flow cytometry and to ask which lineages they ultimately contribute to. Although the
generation of a triple mCherry-CDX4 reporter was ultimately unsuccessful and resulted in KO of
CDX4, single cell transcriptomics allowed for the characterization of CDX4 expressing
mesoderm and the discovery of a surface marker, CD1D, that correlated strongly with CDX4 and
HOXA genes. Isolation of KDR+CD1d-/+ mesoderm under definitive hematopoietic conditions
(CHIR99021+SB431542) confirmed that KDR+CD1d+ mesoderm was greatly enriched for
expression of CDX4 (~20 fold), as well as HOXA7, HOXA9, and CDX1. Although some mildly
CD1d+ cells were found within KDR+CD235a+ primitive hemogenic mesoderm, functional
characterization did not reveal any significant differences in potential, and qPCR of CD1D
demonstrated that it was not appreciably expressed in this population. Both CD1d- and CD1d+
definitive hemogenic mesoderm gave rise to CD34+ endothelium, but only CD1d+ progenitors
were able to give rise to CD4/CD8+ T-cells and were significantly enriched for erythroid and
myeloid colony forming progenitors. These data demonstrate that definitive hematopoietic
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potential is almost entirely restricted to CD1d/CDX4+ mesoderm and that CD1d is positive
marker for definitive hemogenic mesoderm.

4.2 Methods
Culture and differentiation. Hematopoietic differentiations and functional assays were
performed according to the methods in Chapter 2, with the addition of SB431542 (6 μM)
alongside CHIR9902171.
Genome engineering of hPSCs. To generate the 3xmCherry-CDX4 reporter line, the same
CDX4 CRISPR guides were used as before in Chapter 2, but also with plasmid based HDR
template with homology arms containing the in-frame 3xmCherry construct.
scRNA-seq analyses. The scRNAseq datasets were analyzed as described in Chapter 2, but
pseduotime analysis was omitted.
Gene Expression analyses. qRT-PCR was performed as described in Chapter 2.
Flow Cytometry and Cell Sorting. Flow cytometry was performed for hematopoietic
differentiations as previously described, using methods from Chapter 2. CD1d antibody (Clone
CD1d42) was obtained from BD Pharmigen.

4.3 Development of a CDX4 fluorescent reporter
In order to address lineage questions of CDX4 expressing mesoderm, a way to isolate and purify
CDX4+ cells was needed. Due to technical problems associated with using traditional CRE-LOX
recombination systems used in many lineage tracing studies in hPSCs165,166, an in-frame
fluorescent CDX4 reporter design was selected. A design with triple repeat mCherry
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(3xmCherry) and E2A linkers was used167, to aid in robust fluorescence with lower levels of
expression. The construct was designed to be inserted at the 5’ end of CDX4 via homologous
recombination after CRISPR Cas9 mediated double strand breaks (Figure 4.1A). After PCR
genotyping and sanger sequencing confirming correct insertion of the construct, the 3xmCherry
hPSC line was differentiated under basal, high WNT (CHIR99021), and low WNT (IWP2)
conditions and the presence of mCherry fluorescence assessed via microscopy and flow
cytometry (Figure 4.1B). Treatment with CHIR should have induced CDX4-dependent mCherry
expression but unexpectedly, there was no mCherry signal under any culture conditions.
Continued culture with the 3xmCherry line to day 8 revealed there was a distinct lack of
CD34+CD43-CD73-CD184 hemogenic endothelium (HE) under all conditions. Taken together,
these observations suggest there was a disruption in transcription for endogenous CDX4 as a
result of insertion of the 3xmCherry construct, as the CDX4y/- KO hPSCs also displayed a
similarly large reduction in HE. This was likely due to insertion at the 5’ end of CDX4, possibly
disrupting a regulatory element and would likely have functioned better with a 3’ insertion.

4.4 Identifying CDX4+ mesoderm with scRNAseq
With the 3xmCherry-CDX4 reporter disrupting the locus and not displaying any mCherry
expression at expected times during the differentiation, other methods were needed to be able to
address the potential lineages arising from CDX4+ mesoderm. Our lab had recently performed
single cell transcriptomic analysis on our bulk day 3 cultures under definitive
(CHIR99021+SB431542) and primitive (IWP2) hematopoietic conditions. This powerful dataset
would allow for precise transcriptional analysis of CDX4+ cells in the CHIR+SB (CSB) dataset
and could be used to search for potential surface markers that could be used to isolate CDX4
expressing mesoderm. After the cells were processed using the 10X Chromium system, the
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sample sets were sequenced, and the reads aligned and counted using the 10X CellRanger
package. With >6,000 cells identified in each dataset after removing low gene count and
normalized to percent mitochondrial gene expression, the CSB and IWP2 datasets were
integrated using the Seurat software package136, and a UMAP generated to place similar cells
together in two dimensional space. The Seurat clustering algorithm determined that there were
11 distinct clusters of cell types within the integrated UMAP (Figure 4.2A), with variable
contribution from either dataset to each cluster.
In order to determine which cell types were represented within each of the clusters within the
dataset, the expression of several germ layer markers was assessed: NANOG and SOX2 for
pluripotent/primitive streak cells, KRT7, DLX5, and TFAP2A for ectoderm, HNF1B, SOX17, and
FOXA2 for endoderm, and KDR/T for mesoderm (Figure 4.2B). This analysis revealed there
were 5 distinct mesodermal clusters, one of which was composed of GYPA/B/E (cluster 5),
which was comprised mainly of cells from the IWP dataset, suggesting these cells are the
primitive hemogenic mesoderm. Of the remaining four mesoderm clusters, CDX4 expression
was predominately found within clusters 1 and 2, with some expression found within one of the
ectoderm clusters (Figure 4.2C). Having identified the mesodermal cell clusters that are
CDX4+, gene expression analysis could be performed on these clusters using only the cell from
the CSB dataset, enriching for the possibility of identifying definitive hemogenic mesoderm.
When cluster 1 cells were compared to the rest of the cells in the CSB dataset, differentiation
gene analysis revealed a number of HOXA genes, as well CDX1/2 (Table 4.1). Interestingly, one
of the top 30 genes identified was CD1D, a non-canonical MHC receptor found on antigen
presenting cells that binds to various lipid/glycolipid ligands168. It is unclear why CD1D would
be expressed in developing hemogenic mesoderm, as there would be no immune cells in the
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developing embryo at an equivalent timepoint. However, the expression of CD1D was highly
correlated with CDX4 (Figure 4.2D), suggesting that CD1d antibodies could be used to help
purify CDX4+ cells from mesoderm via FACS. Additionally, when all KDR+ cells were
examined for CD1D expression, it was found that CDX4+HOXA+ cells had the highest
proportion of CD1D+ cells, over the only CDX4+ or only HOXA+ cells alone (Figure 4.2E).
While there are CD1D+ cells that are not CDX4+ and vice versa, these data suggest that FACS
isolation of CD1d+ cells could be used to enrich for CDX4+ cells.

4.5 Phenotypic characterization of CD1d+ mesoderm
To test this new potential marker of CDX4 expressing mesoderm, day 3 WT hPSCs
differentiated under definitive (CSB) and primitive (IWP2) hemogenic conditions were harvest
for flow cytometry. KDR+CD235a- mesoderm was assess for CD1d expression, where
approximately 60% of the cells were positive for CD1d gated on FMO controls (Figure 4.3A).
Despite low levels of CD1D+ cells in the IWP2 scRNAseq dataset, KDR+CD235a+ hemogenic
mesoderm also appeared to have some CD1d+ cells, though fewer than KDR+CD235a-. To
confirm the hypothesis that CD1d expression would be surrogate marker for CDX4,
KDR+CD235a-CD1d-/+ (CSB) and KDR+CD235a+CD1d-/+ (IWP2) cells were FACS isolated
and qPCR performed. CDX4 was highly enriched (~20 fold) in KDR+CD1d+ mesoderm over
KDR+CD1d- (Figure 4.3B), validating the previous observations in the scRNAseq dataset. The
CSB derived KDR+CD235a-CD1d+ sorted cells were also confirmed as expressing CD1D at the
transcript level via qPCR, but interestingly the IWP2 derived KDR+CD235a+CD1d+ cells did
not have a significant difference in CD1D expression over the KDR+CD235a+CD1d- cells. This
suggests either that CD1D is being downregulated in this population and only residual protein is
being detected or that the CD1d+ cells are a potential artifact of flow cytometry. The
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KDR+CD235a-CD1d+ cells also had increased expression compared to the KDR+CD235aCD1d- cells for HOXA7, HOXA9, and CDX1, again confirming the informatics analysis that
suggested CD1D+ cells would be enriched for CDX/HOXA expression (Figure 4.3C).

4.6 Functional characterization of CD1d+ mesoderm
Having demonstrated that CD1d+ mesoderm strongly enriches for CDX4+ mesoderm, it is now
possible to ask whether CDX4+ mesoderm gives rise to hematopoietic lineages by using CD1d
as a surrogate surface marker. CD1d-/+ cells were FACS isolated on day 3 of differentiation
from KDR+CD235a- (CSB) definitive KDR+CD235a+ (IWP) primitive hemogenic mesoderm,
followed by reaggregation and continued culture until day 8. Flow cytometry on day 8 of these
four populations revealed a production of mainly CD43+ hematopoietic progenitors from
KDR+CD235a+ mesoderm and the production of CD34+CD43- endothelium from
KDR+CD235a- mesoderm, in line with previous observations of these populations85 (Figure
4.4A). To assess which of these populations could give rise to lymphoid cells, indicative of
definitive hematopoietic potential, either CD34+CD43+ progenitors (IWP2) or CD34+CD43progenitors (CSB) were FACS isolated and cultured with OP9-DL4 stroma under T-cell
promoting conditions. After 22 additional days in culture, flow cytometry of each respective
population revealed that only the KDR+CD235a-CD1d+ mesoderm was ultimately capable of
giving rise to CD45+CD56-CD4/8+ T-cells. Interestingly, some CD56+ cells were generated in
OP9-DL4 culture from the KDR+CD235a+CD1d+ culture. This suggests that perhaps this
population is capable of giving rise to CD56 natural killer (NK) cells, and it has been previously
demonstrated that CD34+CD43+ WNT independent primitive hematopoietic progenitors can
give rise to NK cells34.
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Having demonstrated that lymphoid potential was restricted to KDR+CD235a-CD1d+
mesoderm, myeloid and erythroid lineages also needed to be assessed, to determine whether
KDR+CD235a-CD1d+ is exclusive for definitive hemogenic mesoderm. Additionally, it was
unclear if CD1d was a functional marker for segregating any types of primitive hemogenic
mesoderm. CD34+CD43+ progenitors were FACS isolated on day 8 from reaggregated
KDR+CD235a+CD1d-/+ mesoderm and plated into hematopoietic methylcellulose media and
colonies assessed 8-10 days later. There was no significant difference in myeloid or erythroid
colony forming units between KDR+CD235a+CD1d- and KDR+CD235a+CD1d+ mesoderm,
with only a slightly larger amount of granulocyte forming colonies (Figure 4.4B). When
KDR+CD235a-CD1d-/+ derived CD34+CD43- endothelium was FACS isolated on day 8 and
placed into EHT culture for an additional 9 days72,87, the CD1d+ derived endothelium produced
significantly more floating hematopoietic progenitors compared the CD1d- derived endothelium,
indicating that more cells were likely undergoing the EHT. When the EHT cultures were
harvested and plated into hematopoietic methylcellulose media and colonies counted after 12-14
days, the majority of erythroid and myeloid colonies were restricted to the CD1d+ mesoderm,
with 3/6 replicates being completely absence of any hematopoietic colonies. Taken together,
these data demonstrate that CD1d is a marker of definitive hemogenic mesoderm, as
KDR+CD235a-CD1d+ mesoderm contains nearly all definitive lymphoid, myeloid, and
erythroid potential in a high WNT, low TGFβ culture.

4.7 Discussion
Despite the failure of the 3xmCherry-CDX4 reporter to effectively label CDX4+ mesoderm and
disruption of endogenous expression, scRNAseq allowed for the identification of a correlate
marker, CD1d. The isolation of CD1d+ mesoderm enriched not only for CDX4/HOXA
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expressing cells, but also nearly all definitive hematopoietic potential, representing a novel
marker for definitive hemogenic mesoderm. It still remains unclear why CD1d is being
expressed in this particular developmental population and why it is correlated with hemogenic
mesoderm. Given that CD1d responds not only to foreign glycolipids from bacteria and other
organism, but also to endogenously produced glycolipids169, it is possible that it is being utilized
in some regulatory manner in these cell types. There is some evidence that CD1d regulates HSC
potential and function, albeit in a non-cell autonomous manner170; perhaps CD1d also plays a
role in the endothelial to hematopoietic transition. Treatment with α-galactosylceramide or other
CD1d ligand could test these possibilities169, perhaps leading to an inflammatory response in
these cell types or some other, poorly understood effect.
In addition to understanding why CD1d is expressed in these cell types, there is also the question
of how it becomes expressed in these cell types. Cursory experiments using the CDX4-/y KO line
suggested that CD1d expression at day 3 was not affected by loss of CDX4. Additionally, data
from paired ChIP/RNAseq of mesoderm isolated from the CDX4-/y, iCDX4 rescue line revealed
no CDX4 binding peaks near the CD1D locus, nor any changes in the gene expression as a result
of CDX4 induction via DOX treatment. This would suggest that CD1d is simply a correlative
mesodermal marker and is not directly regulated by CDX4. Analysis of expression in mouse
scRNAseq gastrulation datasets revealed the expression of Cd1d1 within some mesodermal cells,
suggesting that its expression is also found in in vivo and within other species at a correlate
timepoint (E7.25, E7.5)171. In this dataset, Cd1d1+ cells did not overlap significantly with Cdx4
expressing cells, perhaps suggesting species differences, though whether CD1d protein is
detectable in these populations or the lineages that Cd1d1 expressing mesoderm in the mouse
gives rise to is not known. Given that CD1d expression was lower in IWP2 treated
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KDR+CD235a+ primitive hemogenic mesoderm, it is possible that the WNT agonist
CHIR99021 that is used to specify definitive hemogenic mesoderm is leading to this increase in
CD1d. The TGFβ inhibitor SB431542 was also used to aid specification of CDX/HOXA+
hemogenic mesoderm as demonstrated by others118, which could also leading to an increase in
CD1d expression, as TGFβ signaling has been shown to inhibit CD1d expression172. Perhaps the
inhibition of TGFβ is leading to the expression of CD1d and by testing varying concentrations of
SB431542 or adding the Nodal ligand activin A, which is also inhibited by SB431542, could
lead to some insight on what regulates CD1d expression. Regardless, the identification of this
novel marker allows for greater purification of CDX4+ definitive hemogenic mesoderm and
CD1d can be used as a selection marker to purify mesoderm and allow for greater interrogation
of further lineage questions.
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Figure 4.1: Design and test of an in-frame CDX4 reporter line
A. A schematic of the CDX4 locus, detailing the design of a triple mCherry (3xmCherry)
florescent construct to be placed at the 5’ end of exon 1 of CDX4, through homologous
recombination after cleavage with CRISPR Cas9. B. The CDX4 3xmCherry hPSC line was
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differentiated to day 3 mesoderm with BMP4/bFGF/activin A, as well as to definitive hemogenic
mesoderm via CHIR99021 (CHIR) treatment, or primitive hemogenic mesoderm with IWP2
treatment. Flow cytometry was performed to assess for the formation of KDR+ mesoderm, as
well as to assess for CDX4 dependent mCherry expression. C. CDX4 3xmCherry hPSCs were
differentiated to day 8 hemogenic endothelium stage under established conditions and flow
cytometry performed. Shown gated on CD34+ cells, looking at endothelial markers CD184 and
CD73.
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Figure 4.2: scRNAseq of allows for characterization of CDX4+ mesoderm and
reveals CD1D as a potential surface marker
A. scRNAseq was performed on bulk culture treated with CHIR99021 and SB431542 (CSB) or
IWP2 at day 3, after the specification of mesoderm to better assess the culture heterogeneity and
to find hemogenic mesoderm. Briefly, the cells were dissociated via trypsin and fixed in
methanol, before being processed via 10X Genomics Chromimum 3’ kit, capturing >6000 cells
per sample set. The libraries were sequencing via an Illumina HiSeq 3000 and processed via the
Cell Ranger pipeline. The Seurat v3 R package was used to integrate the cells from the CSB and
IWP2 datasets and organize them into two-dimensional space via UMAP. Clustering of the cells
was then performed using the Seurat algorithm, resulting in 11 algorithmically distinct clusters
denoted by different colors. On the right, the contribution of each sample (CSB in blue or IWP2
in red) is shown to each region of the UMAP. Presumptive identity of each cluster is indicated by
colored circle (pluripotent/primitive streak - blue, ectoderm - green, endoderm - yellow, and
mesoderm - red). B. Expression of various pluripotent/primitive streak (blue), ectoderm (green),
endoderm (yellow) and mesoderm (red) genes was assess via dot plot, where the expression of
each gene is shown for a particular cluster. Size indicates relative numbers of cells expressing a
particular gene in the given cluster, blue color intensity indicates average relative level of
expression among cells in the cluster. C. Expression of CDX4 shown on the UMAP (within only
the CSB cells), where darker blue indicates higher expression. D. Expression of CD1D shown on
the UMAP (within only the CSB cells), where darker blue indicates higher expression. E. Violin
plot of the CD1D expression of different KDR+ cell types with or without expression of CDX4
or HOXA genes. Dots indicate individual cells, and the colored outline indicates quantiles based
on the total number of cells.
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Figure 4.3: Phenotypic characterization of CD1d expressing cells within day 3
mesoderm
A. Representative flow cytometry of both CHIR99021/SB431542 (CSB) and IWP2 treated day 3
cultures for KDR, CD235a, and CD1d. KDR+CD235a- definitive hemogenic mesoderm and
KDR+CD235a+ primitive hemogenic mesoderm were then assessed for the expression of CD1d
in the plots on the right. B. KDR+CD235a-CD1d-/+ and KDR+CD235a+CD1d-/+ populations
were isolated via FACS for RNA, in order to make cDNA and perform RT-qPCR for CDX4,
CD1D, and GYPA. n = 3, ** p < 0.01, *** p < 0.001 via students t test. C. Expression of CDX
and HOXA genes via qPCR in KDR+CD235a-CD1d-/+ FACS isolated cells. n =3, * is p < 0.05
via students t test, error bars SEM.
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Figure 4.4: Functional characterization of CD1d+ mesoderm
A. Representative flow cytometry plots of CHIR99021/SB431542 (blue) and IWP2 (red)
differentiated hPSCs, sorted on day 3 for KDR+CD235a-/+CD1d-/+ and reaggregated for an
additional 5 days and harvested again for FACS on day 8. IWP2 treated samples were then FACS
isolated for CD34+CD43+ and CSB samples for CD34+CD43- progenitors and cultured on OP9DL4 stroma under T-Cell promoting conditions to test for lymphoid potential after 22 days of
culture. Cells were then harvested for flow cytometry, CD45+CD56- (middle flow plots)
progenitors were then gated to exclude natural killer cells and assessed for CD4/CD8 T-cells
(right flow plots). B. Day 3 sorted KDR+CD235a+CD1d-/+ (IWP2) or KDR+CD235a-CD1d-/+
(CSB) hemogenic mesoderm was isolated and reaggregated for an additional 5 days, flowed by a
second FACS isolation of CD34+CD43+ (IWP2) or CD34+CD43- (CSB) progenitors, which
were seeded into hematopoietic methylcellulose media for colony forming assays (after
additional EHT culture for CSB CD34+). The numbers of colonies were then assessed after 8-10
days (IWP2) or 10-12 days (CSB) and the numbers were counted of burst forming units
erythroid (BFU-E) and colony forming units (CFU) of erythroid (E), granulocyte (G), myeloid
(M), and mixed granulocyte/myeloid (GM). IWP2 n=4, CSB n =6, error bars SEM.
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Table 4.1: CD1D identified as a DEG in UMAP cluster 1
Cluster 1 from the Seurat generated UMAP projection of scRNAseq of hemogenic mesoderm
was identified as having mesodermal markers such as KDR, as well as a large number of CDX4+
cells. Taking only the CSB derived cells from this cluster (further enriching for CDX4+ cells)
and then performing DEG analysis in comparison to the rest of the CSB culture revealed a
multitude of DEG’s, including several HOXA and CDX genes (highlighted in red). Displayed is
the top 30 differentially expressed genes ordered by padj value, CD1D highlighted in green.
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Chapter 5: Discussion
5.1 CDX4 in hematopoietic development
True functional assessment via engraftment studies in immunocompromised mice of mesoderm
induced iCDX4 hematopoietic progenitors was not assessed in this work, questioning whether
CDX4 can be truly termed as a ‘regulator’ of definitive hematopoiesis. While T cell potential was
found to be reduced in frequency as a result of loss of CDX4 and restricted to a
KDR+CD1d+CDX4+ mesodermal progenitors, the presence of lymphoid potential is not
sufficient to characterize these as definitive hematopoietic progenitors. The existence of lineages
such as the LMPP53 in mouse development that give rise to lymphoid progenitors independent of
the HSC suggests that this metric alone cannot be used alone to denote definitive, HSC
dependent hematopoiesis. Speculating on whether enforced mesodermal CDX4 expression would
result in the production of an engraftable progenitor, it is probable that CDX4 expression alone
would be insufficient to specify a true HSC for several reasons. The first being that mesodermal
CDX4 expression only lead to comparable levels of progenitors as mesodermal WNT agonism
when measured by colonies in methylcellulose, suggesting that WNT agonism alone is able to
activate CDX4 with the same functional consequences as overexpression. Secondly, CDX4y/- did
not lead to a complete loss of erythro-myleloid-lymphoid bearing HE, suggesting perhaps CDX4
simply influences the amount of HE specified, not necessarily its lineage potential or ability to
engraft. Thirdly, other transgenic approaches to producing an HSC in vitro have need a
minimum of seven transcription factors activated post EHT in order to produce an engraftable
progenitor173. While three of these factors were HOXA genes and appear to activated by CDX4 at
an early stage after mesoderm specification, overexpression of ERG, LCOR, RUNX1, and SPI1,
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were also required to produce an engraftable progenitor. In this work, none of these genes are
activated by mesodermal CDX4 expression at any measured stage, suggesting that there are other
regulatory signals that are likely needed outside of CDX4 that lead to the upregulation of these
factors and ultimately specification of an engraftable progenitor. For similar reasons, enrichment
of CDX4+ mesoderm using FACS of KDR+CD1d+ cell is also unlikely to result in the
specification of an engraftable progenitor
Despite these caveats, this work demonstrates CDX4 appears to regulate the development of
human definitive-like hemogenic mesoderm through genetic studies. Important questions are still
raised, however, when examining the literature surrounding CDX4 in other model systems. In the
zebrafish, cdx4 KO appears to affect all waves of hematopoiesis112,130, as the area known as the
interior cell mass (ICM), where primitive hematopoiesis occurs in the zebrafish174, also displayed
deficits in hematopoiesis. Additionally, in mouse embryonic stem cells models, Cdx4 induction
appeared to positively regulate primitive hematopoiesis84,114 and KO of Cdx4 in E8.5 mouse
embryos lead to a deficit in primitive hematopoietic progenitors113. This directly contrasts the
results from our differentiation model system, where loss of CDX4 lead to an expansion in
primitive hematopoiesis and a deficit in definitive.
What could explain these contrasting results? Perhaps some of the explanation could also lie in
species differences between CDX and HOX gene expression; zebrafish have only 2, instead of 3
cdx genes: cdx4 and cdx1a. Although it is broadly assumed that CDX genes are redundant in
their functions106,107,130, but perhaps the absence of one CDX gene in the zebrafish could explain
the differences in their regulation and expression. As for the mouse, it is less clear what could be
causing these differences in CDX dependent regulation of hematopoiesis. Some of these
differences could be a result of timing of the stages of hematopoietic development, which is
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faster in mouse pluripotent stem cell differentiations compared to hPSCs. Additionally, the
aforementioned functional analysis of Cdx4 KO mouse yolk sacs on embryonic day 8.5113 would
also capture the erythro-myeloid progenitors (EMPS) at this particular time point48,120, which
could suggest that the EMP in the mouse might be dependent on Cdx4. The primitive program
has also showed to be dependent on WNT activation in mouse pluripotent stem cell
differentiations86, whereas the opposite is true in hPSCs, as the primitive program is independent
of WNT signaling85. Interestingly, in other studies there was no overt hematopoietic phenotype
in Cdx4 KO mice, which appeared normal and healthy despite apparent reductions in yolk sac
hematopoiesis175.
Although not capable of an HSC, the EMP in the mouse gives rise to more mature erythrocytes
and granulocytes, as well as natural killer cells34 and has sometimes been termed as a
“definitive” hematopoietic progenitor with more in common with the HSC than other primitive
yolk sac progenitors176. Perhaps the CDX4 dependent population in our hPSC differentiation
model could resemble a human EMP, though the mouse EMP does not have lymphoid/T-Cell
potential (excepting natural killers), whereas our CDX4 dependent definitive progenitors are
capable of robust T-cell production on OP9-DL4 stroma. There is also in vivo evidence that the
human aorta gonad mesonephros (AGM) region where the HSC emerges is highly enriched for
HOXA genes118, again supporting the idea that CDX4/HOXA expression is correlative of a
definitive hematopoietic progenitor. Observations from our lab suggest that KDR+CD184CDX4+ mesoderm gives rise to hematopoietic progenitors independent of retinoic acid signaling,
which the HSC is known to dependent on147, but it has not been assessed whether CDX4 KO
would affect the specification of KDR+CD184+CDX4lo retinoic acid dependent hematopoiesis.
Another possibility is that CDX4 dependent hematopoiesis could represent a definitive, intra86

embryonic hemogenic endothelium that is incapable of giving rise to an HSC; recent single cell
transcriptomics of early human embryos identified two transcriptional distinct waves of
hemogenic endothelial cells in the embryo proper, one that appeared primed for HSC
specification and one not71. Whether the EMP or human equivalent of the EMP is dependent on
CDX4, or the CDX4 dependent HE in our system represent an ‘early’ hemogenic endothelium
that does not produce an HSC, this work advances the intricate and complicated field of
embryonic hematopoietic development.
Now that CDX4+ mesoderm can be isolated effectively through the use of CD1d as a correlative
marker, further questions on what lineages in our system arise from CDX4+ cells. It appears
based on our informatics data that the CD184-, CDX4+, CYP26A1+, retinoic independent
mesoderm also expresses CD1D. This would indicate that CDX4+ mesoderm is likely giving rise
to retinoic acid independent hematopoiesis, although CDX4 and CD184 are not mutually
exclusive. The ability of KDR+CD235a-CD1d-/+ mesoderm to give rise to retinoic dependent
hematopoiesis has not been tested, though it is likely that KDR+CD1d- mesoderm might
represent the CD184+ALDH1A2+CYP26A1- retinoic acid dependent hemogenic mesoderm.
This hypothesis is further supported by the fact that exogenous CDX4 results in the expression of
CYP26A1, which is expressed under normal, WT conditions in the KDR+CD184- mesoderm.
Additionally, the HOXA signature of CD184- mesoderm was recapitulated in the CD184+
mesoderm when CDX4 expression was enforced, suggesting that exogenous CDX4 might
convert CD184+ retinoic acid dependent mesoderm to a CD184- like retinoic acid independent
mesoderm. The summarized model of these observations and hypothesizes are displayed in
Figure 5.1.
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It is still unclear how CDX4 is leading to the repression of the primitive program from the paired
ChIP/RNAseq experiments. Crosstalk between CDX and WNT signaling has been observed in
different contexts84,108,109, and it could be possible that CDX4 induction is leading to an
upregulation of WNT signaling, which could be repressing the primitive program as has been
previously observed85. Looking at genes that were targeted by CDX4, both WNT5A and WNT5B
were induced as a result of enforced CDX4 expression, though these ligands are known to
stimulate the non-canonical or β-catenin independent WNT signaling177. Given that low levels of
β-catenin are needed to produce primitive hemogenic mesoderm85, the induction of CDX4
leading to more non-canonical WNT and further suppression of β-catenin does not support a
WNT-CDX4 based repression of primitive hematopoiesis. Changes in FZD6, 7, and 8 were also
observed in CD235a+ primitive hemogenic mesoderm after induction of CDX4, further
complicating the possible interactions, making it difficult to formulate a hypothesis of a precise
mechanism for the WNT related suppression of primitive hematopoiesis. Further study will be
needed to tease out the precise nature of this relationship, perhaps through the use of different
WNT ligands or genetic studies with KO’s of various WNT receptors.
With the knowledge that CD184 and CD1d are markers segregating (potentially) very different
types of definitive hemogenic mesoderm, future studies can tease out the precise lineage
contributions of these mesodermal populations to CDX4-dependent/independent and retinoic
acid-dependent/independent hematopoiesis. The genetic tools also provided as a result of this
work, including the CDX4-/y, iCDX4 rescue line will also allow for testing the dependency of
retinol responsive hematopoiesis on CDX4. The link between CDX4 and medial HOXA genes is
also strongly suggested in the work, though the precise population dependent relationships will
need to be teased out using genetic complementation studies. These advances will also provide a
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foundation to further improve the hematopoietic differentiation of hPSCs, providing a more pure
and better defined hemogenic mesoderm. Knowledge of the role of CDX4 also provides an
indicator of definitive hematopoietic potential and can be leveraged to find culture conditions
that increase its expression and perhaps, eventually, the HSC.

5.2 CDX4 in cardiac development
The discovery that CDX4 is negatively regulating the expression of TBX20 directly lead to the
hypothesis that CDX4 expression represses cardiomyocyte specification, which was
demonstrated functionally using the CDX4-/y, iCDX4 rescue line. Although similar observations
had been found in mouse embryonic stem cells and zebrafish159, as well as in mouse embryos158,
the mechanism of how CDX gene expression lead to a repression of the cardiac program was not
clear. It is possible that CDX4 protein binding to an enhancer or regulatory region could recruit
other factors that lead to a suppression of genes such as TBX20, through inactivation of these
regions. While CDX genes were found to interact with chromatin remodelers such as
SWI/SNF154, it is unclear if CDX4 working in a similar manner, as SWI/SNF generally opens
chromatin, whereas in this work it appears to be repressive. Additional experiments will be
necessary to show a non-canonical, repressive function of CDX4 outside of its known function as
a transcription factor. DNA Binding motif analyzes of these CDX4-bound regions could reveal
partners that could be acting cooperative with CDX4, though it is possible that CDX4 protein
might be the only member of a putative complex that directly binds to DNA. To address this
possibility and to more directly discover binding partners, lysates from differentiated mesoderm
could be probed with FLAG-CDX4 protein and mass spectrometry performed to find enriched
these partners. Without these analyzes identifying possible repressive binding partner for CDX4,
there still remains the possibility that CDX4 binding near TBX20 is simply a coincidence and the
89

transcriptional repression seen is resulting from unknown indirect regulation from CDX4 acting
on another gene or genes.
Evidence of a common origins and opposing, intertwining genetic regulation of cardiac lineages
and the primitive hemangioblast has been hinted at in the literature previously. Exogenous
activation of notch signaling in mouse pluripotent stem cell differentiations was able to respecify
hemangioblast containing populations to cardiac cells95. Additionally, loss of Scl in mouse
embryos lead to the exogenous production of beating cardiomyocytes from yolk sac
endothelium96. In the ChIP/RNAseq of KDR+CD235a+ mesoderm, there were no changes in
TAL1(SCL) or in components of the notch signaling pathway between KO of CDX4 and CDX4
induction, which is somewhat surprising given that cdx4 was found to bind and activate scl in
zebrafish131. It is possible that changes in these genes/pathways might become apparent in later
stages in of the differentiation post mesoderm formation and that CDX4 might result in indirect
activation of notch or TAL1. It is also unclear if the increase in cardiomyocytes seen as a result of
loss of CDX4 represents the conversion of progenitors to the cardiac lineage, or if there if there is
simply an expansion of cardiomyocyte progenitors as a result of the formation of less hemogenic
mesoderm.
The observation that ventricular cardiac progenitors arise from a CD235a+ mesoderm134, low in
CDX4 expression, strongly suggests that CDX4 is playing an important gate keeper role in
cardiac specification, potentially by promoting hematopoietic lineages over cardiac. Although it
has not been proven functionally, it is likely that day 3 KDR+CD235a+ progenitors are the
source of ventricular cardiomyocytes as well as primitive hemogenic mesoderm. Whether
CD235a markers both hemogenic and cardiogenic mesoderm or whether KDR+CD235a+
mesoderm represents a dually cardiac/hematopoietic capable population is not precisely clear.
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Additionally, the knowledge that a retinol responsive mesoderm population that gives rise to
atrial cardiomyocytes134 could indicate that atrial cardiac progenitors might resided with
KDR+CD184+ mesoderm. Given that this population is low in CDX4 and CYP26A1 expression,
while high in ALDH1A2, and clearly responsive to retinol in a hematopoietic context, cardiac
promoting conditions might reveal that CD184+ is also capable of atrial cardiomyocytes.
Observations in zebrafish suggest that effects on cardiac development due to loss of cdx genes is
dependent on concomitant inhibition of retinoic acid signaling159. This hypothesis would also
suggest that not only is CDX4 repressing ventricular cardiomyocytes through direct repression of
TBX20 and indirect repression of other factors (perhaps through CDX2), but CDX4 might also be
repressing atrial cardiac progenitors through induction of CYP26A1.
These predications could represent a more in-depth understanding of which types of mesoderm
both hematopoietic and cardiac progenitors come from, summarized in Figure 1. If true, this
greater model of what mesoderm gives rise to which progenitor could have great implications for
hematopoietic and cardiac differentiation protocols. Ensuring the correct types of mesoderm are
specified at outset of a differentiation has a large impact of the efficiency and numbers of the
target cell type. Reducing the expression of CDX4 during mesoderm formation could possibly be
used to enhance the differentiation of ventricular cardiomyocyte differentiations, and possibly
atrial cardiomyocyte differentiations as well. Given that the treatment of the WNT inhibitor
IWP2 from days 3-5 is critical for cardiomyocyte differentitation178, it is possibly that this leads
to low CDX gene expression and thus prevents CDX dependent inhibition of cardiomyocyte
transcription factors. Further experimentation with FACS isolation of these different
mesodermal populations, as well as under various will be needed to determine if these

91

observations will be supported by the data and applicable to improving existing cardiomyocyte
differentiation protocols.
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Figure 5.1 Model of early mesodermal development in hPSCs
Within mesoderm under high WNT conditions, KDR+CD184-(CD1d+) ROH independent
hemogenic mesoderm is specified, having a CDX4+HOXA+CYP26A1+ gene signature,
ultimately giving rise to erythro-myelo-lymphoid definitive hemogenic endothelium. High WNT
conditions also give rise to KDR+CD184+(CD1d-) ROH dependent hemogenic mesoderm, with
lower levels of CDX4 expression, allowing for expression of TBX20 and leading to low
CYP26A1 expression. This population likely also gives rise to atrial cardiomyocytes, in addition
to ROH-dependent erythron-myelo-lymphoid hematopoiesis. Lastly, under low WNT conditions
a KDR+CD235a+ that is CDX4- is produced. This lack of CDX4 expression allows for increased
TBX20 expression, as well as induction of other cardiac related transcription factors, leading to
the specification of ventricular cardiomyocytes. This population gives rise to primitive
hematopoietic progenitors through an unknown, but low WNT dependent mechanism.
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